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ABSTRACT 
 
This is a descriptive, comparative hospital based study. The 
study was conducted in the pediatric wards of some hospitals of 
Khartoum state, and in the sickle cell disease referral clinic in 
Khartoum Children Emergency Hospital. Study period was 
from September to December 2004. 
The aim of this study was to determine the prevalence of 
Parvovirus B19 infection and to identify the correlation between 
B19 virus and a plastic crisis in children with 
hemoglobinopathies. The study population comprised of 180 
children, between one month to 18 years of age, of whom 75 
children had homozygous sickle cell (SS) disease, 13 
thalassemic children, 2 patients with hemoglobin SC and 90 
control children with a normal hemoglobin (AA). 
The prevalence of parvovirus B19 IgG antibody in children with 
hemoglobinopathies was found to be 31.1% while in normal 
children was found to be 26.7%. The incidence of acute 
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infection, (a plastic crises) designated by a positive parvovirus 
IgM antibody, was 6.7% among patients with 
hemoglobinopathies and 2.2% in normal children. The co-
related factors between parvovirus B19 and a plastic crises were 
only found to be of significant difference in the case of poor 
housing condition (P < 0.001). 
As parvovirus B19 infection is discovered to be widely 
prevalent in the Sudan by this study, so our recommendation is 
to establish the screening program in all blood banks and to 
conduct the diagnosis and treatment program specially for 
hemoglobinopathies.   
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  ﻣﻠﺨﺺ ﺍﻷﻃﺮﻭﺣﺔ
ﺓ ﻤﺴﺘﺸﻔﻴﺎﺕ ﻓﻲ ﺃﺠﺭﻴﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻜﺩﺭﺍﺴﺔ ﻭﺼﻔﻴﺔ ﻓﻲ ﻋﻨﺎﺒﺭ ﺍﻷﻁﻔﺎل ﺒﻌﺩ
ﺍﻟﺨﺭﻁﻭﻡ ﻭﺍﻟﻌﻴﺎﺩﺓ ﺍﻟﻤﺤﻭﻟﺔ ﻟﻤﺭﺽ ﺍﻷﻨﻴﻤﻴﺎ ﺍﻟﻤﻨﺠﻠﻴﺔ ﻭﻤﺴﺘﺸﻔﻰ ﺤﻭﺍﺩﺙ ﺍﻷﻁﻔﺎل 
  .ﺍﻟﺨﺭﻁﻭﻡ ﻓﻲ ﺍﻟﻔﺘﺭﺓ ﻤﺎ ﺒﻴﻥ ﺸﻬﺭﻱ ﺴﺒﺘﻤﺒﺭ ﻭﺩﻴﺴﻤﺒﺭ
ﺒﻴﻥ 91ﻭﺍﻟﻬﺩﻑ ﻤﻥ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻫﻲ ﻤﻌﺭﻓﺔ ﻨﺴﺒﺔ ﻓﻴﺭﻭﺱ ﺍﻟﺒﺎﺭﻭ ﻓﻴﺭﻭﺱ ﺭﻗﻡ 
ﻼﻨﻤﻭﻴﺔ ﺒﻴﻥ ﻤﺭﺽ ﺍﻻﻋﺘﻼل ﺍﻟﺨﻀﺎﺒﻲ ﻭﻤﻌﺭﻓﺔ ﻋﻼﻗﺔ ﻫﺫﺍ ﺍﻟﻔﻴﺭﻭﺱ ﻭﺤﺩﻭﺙ ﺍﻟﻨﻭﺒﺔ ﺍﻟ
  .ﻤﺭﺽ ﺍﻻﻋﺘﻼل ﺍﻟﺨﻀﺎﺒﻲ
 81ﻤﺭﻴﺽ ﺘﺘﺭﺍﻭﺡ ﺃﻋﻤﺎﺭﻫﻡ ﻤﺎ ﺒﻴﻥ ﺸﻬﺭ ﻭ  081ﻭﻗﺩ ﺃﺠﺭﻴﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻓﻲ 
ﻤﺭﻴﺽ ﻴﻌﺎﻨﻭﻥ ﻤﻥ ﺍﻷﻨﻴﻤﻴﺎ 57ﻭﻫﻭ ﻴﺸﻤل ، ﺴﻨﺔ ﻴﻌﺎﻨﻭﻥ ﻤﻥ ﻤﺭﺽ ﺍﻻﻋﺘﻼل ﺍﻟﺨﻀﺎﺒﻲ
ﻤﺭﻴﺽ ﻤﻥ ﺃﻨﻴﻤﻴﺎ ﺍﻟﺒﺤﺭ ﺍﻷﺒﻴﺽ ﺍﻟﻤﺘﻭﺴﻁ ﻭﻤﺭﻴﻀﻴﻥ ﻤﻥ ﺍﻨﻭﺍﻉ ﺍﺨﺭﻱ 31ﻭ ،ﺍﻟﻤﻨﺠﻠﻴﺔ
  .ﻁﻔل ﺫﻭ ﺨﻀﺎﺏ ﺍﻟﺩﻡ ﺍﻟﻁﺒﻴﻌﻲ 09ﻀﺎﺒﻲ ﻭ ﻤﻥ ﺍﻻﻋﺘﻼل ﺍﻟﺨ
ﺒﻴﻥ % 1.13ﻭﻗﺩ ﻭﺠﺩﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺃﻥ ﻨﺴﺒﺔ ﺇﻴﺠﺎﺒﻴﺔ ﺍﻨﺘﺸﺎﺭ ﻫﺫﺍ ﺍﻟﻔﻴﺭﻭﺱ ﻫﻭ 
ﺒﻴﻥ ﺍﻷﻁﻔﺎل ﺫﻭ ﺍﻟﺨﻀﺎﺏ ﺍﻟﺩﻡ ﺍﻟﻁﺒﻴﻌﻲ ﺒﻴﻨﻤﺎ % 7.62ﺃﻁﻔﺎل ﺍﻷﻋﺘﻼل ﺍﻟﺨﻀﺎﺒﻲ ﻭ 
ﺒﻴﻥ ﺍﻷﻁﻔﺎل ﻤﺭﺽ ﺍﻷﻋﺘﻼل ﺍﻟﺨﻀﺎﺒﻲ % 7.6ﻨﺴﺒﺔ ﺇﺼﺎﺒﺘﻬﻡ ﺒﺎﻟﻨﻭﺒﺔ ﺍﻟﻼﻨﻤﻭﻴﺔ ﻫﻲ 
  .ﻥ ﺍﻷﻁﻔﺎل ﺫﻭﻱ ﺨﻀﺎﺏ ﺍﻟﺩﻡ ﺍﻟﻁﺒﻴﻌﻲﺒﻴ%2.2ﻭ
ﻭﻗﺩ ﻭﺠﺩﺕ ﺍﻴﻀﺎ ﻓﻲ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻥ ﺍﻟﻌﺎﻤل ﺍﻟﻭﺤﻴﺩ ﺍﻟﻤﻭﺜﺭ ﻭﺍﻟﺫﻱ ﻟﻪ ﻋﻼﻗﺔ 
  .ﺒﺎﻨﺘﺸﺎﺭ ﺍﻟﻔﻴﺭﻭﺱ ﻫﻭ ﺤﺎﻟﺔ ﺍﻟﻤﻨﺎﺯل ﺍﻟﻤﺘﺭﺩﻴﺔ
ﻭﺍﺴﻊ ﺍﻻﻨﺘﺸﺎﺭ ﻓﻲ  91ﻭﻤﻥ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻓﻘﺩ ﻭﺠﺩ ﺍﻥ ﺍﻟﺒﺎﺭﻓﻭﻓﻴﺭﺱ ﺭﻗﻡ 
ﻲ ﻜل ﺒﻨﻭﻙ ﺍﻟﺩﻡ ﺒﺎﻟﺴﻭﺩﺍﻥ ﻓﻠﺫﺍ ﻨﻭﺼﻲ ﺒﻌﻤل ﺒﺭﻨﺎﻤﺞ ﻓﺤﺼﻲ ﻟﻬﺫﺍ ﺍﻟﻔﻴﺭﻭﺱ ﻓ، ﺍﻟﺴﻭﺩﺍﻥ
71 
ﻭﺍﻨﺸﺎﺀ ﺒﺭﻨﺎﻤﺞ ﻟﺘﺸﺨﻴﺹ ﻭﻋﻼﺝ ﻤﺭﻀﻲ ﻫﺫﺍ ﺍﻟﻔﻴﺭﻭﺱ ﺨﺼﻭﺼﺎ ﻤﻥ ﻤﺭﻀﻲ 
  .ﺍﻻﻋﺘﻼل ﺍﻟﺨﻀﺎﺒﻲ
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 18
  
LISTS OF FIGURES 
 
Fig (1)    Age distribution of the study population------------------------90 
Fig (2)    Gender distribution of the study population-------------------91 
Fig (3)  Residence of children of the study population-------------------92 
Fig (4)    Tribal distribution of the study population---------------------95 
Fig (5)Consanguinity of parents of the study population---------------96 
Fig (6)   Family history of Hemoglobinopathies among  
                    Children in the study group-------------------------------------97 
Fig (7)    The standard of education of children in the 
                       Study group------------------------------------------------------101 
Fig (8)    Father’s educational level in the study group-----------------102 
Fig (9)     Mother’ educational level in the study group----------------103 
Fig (10)   Father’ occupation in the study group-------------------------104 
Fig (11)    Mother’ occupation in the study group-----------------------105 
Fig (12)    The type of housing in the study group-----------------------106 
Fig (13)    Socioeconomic status in the study group---------------------107 
 
 19
Fig(14)     The age of presentation of patients with     
                       Hemoglobinopathies------------------------------------------110 
Fig (15)    The age of diagnosis of Hemoglobinopathies---------------111  
Fig (16)    The different types of Hemoglobinopathies in  
                    Children of the study group-----------------------------------112 
Fig(17) Number of blood transfusion in the study group------------117 
Fig (18) Weight of the children of the study population---------------121 
Fig (19) Height of the children of the study population----------------122 
Fig (20) Parvovirus B19 (IgG) antibodies in the study 
                     Group (seroprevalence) ----------------------------------------128  
Fig (21)    Parvovirus B19 (IgM) antibodies group-----------------------129 
Fig (22)    Age distribution of seropositive group------------------------130 
Fig (23)     Sex distribution of seropositive group------------------------131 
Fig (24)     Type of hemoglobinopathies among 
                          Seropositive group -------------------------------132 
Fig (25)     Number of blood transfusion in seropositive 
                      Group -------------------------------------------- -----139 
 
 20
LISTS OF TABLES 
  
Table (1)    Number of hospital admission among children  
                     In the study population ----------------------------------------113 
Table (2)    Risk factors in the study population--------------------------116 
Table (3)     Clinical symptoms in the study population--------------120 
Table (4)     Clinical signs in the study population---------------------123                       
Table (5)     Number of hospital admission in patients of       
                    (IgG)  seropositive group -------------------------------------133 
Table (6)    Number of hospital admission in patients of  
                      (IgM)  seropositive group -----------------------------------134 
Table (7)     Risk factors among seropositive (IgM) group  
                      (Aplastic crisis)  -----------------------------------------------138 
Table (8)   Clinical symptoms among seropositive (IgM)  
                      Group (Aplastic crisis) --------------------------------------142 
Table (9)      Clinical   signs among seropositive (IgM) 
                      Group (Aplastic crisis) --------------------------------------143 
 
 21
1.1 Historical Background:- 
               Parvovirus B19 was discovered in 1975 by the Australian 
virologist   Cossart and his colleagues, who had unexpectedly found 
viral particles in the sera of asymptomatic patients that were 
screened for hepatitis infection. Biochemical and molecular 
characteristics subsequently demonstrated these particles as 
parvovirus. Because specimen 19 of panel B contained the 
unexpected virus, the parvovirus B19 was so designated (1). 
Five years later the Parvovirus B19 was described in Japan as 
Nakatani virus. (2) In 1980, a brief and uneventful febrile episode was 
noted in two soldiers and B19 was detected in serum by using 
Electronic Microscopy (3). 
             There was still no disease distinctly connected with the virus 
until an association with transient aplastic crisis in patients with sickle 
cell anemia was observed in 1981. Sera from Jamaicans children 
residing in London were observed to contain Parvovirus B19 antigen 
at the time of aplastic crisis, while convalescent Phase sera showed 
evidence of sero-conversion. (4) 
           Two years later, Erythema Infectiosum was sero-
epidemiologically linked to Parvovirus B19 infection in healthy 
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children. Shortly thereafter another syndromes related to B19 
infection were described such as fetal losses, arthritis and pure red 
cell aphasia. (6)  
            In 1985, the virus was recognized as member of the 
parvoviridae, given the name B19 by the international committee on 
taxonomy of viruses. (7)   
1.2 Classification:-  
           The classification of the family parvoviridae relies on 
morphology and functional characteristics. Parvoviruses are smallest 
DNA containing viruses able to infect mammalian cells. Based on the 
ability to infect vertebrate cells, the parvoviridae are divided into 
parvovirinae and densovirinae  respectively (8) 
            Parvovirinae are subdivided into three genera according to 
their transcription maps, the nature of the terminal repeats, and the 
ability to replicate either autonomously (genus parvovirus), with 
helper virus (genus dependovirus), or preferentially in erythroid cells 
(genus Erythrovirus). Only members of Dependovirus and 
Erythrovirus genera are known to infect humans. (8)  
             Parvovirus B19 is autonomous in the sense that it does not 
require the presence of a helper virus so it was classified in the genus 
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parvovirus since replication only occurs in erythrocyte precursors, 
parvovirus B19 is now classified as a member of the Erythrovirus 
genus.(8) 
1.3 Structure and morphology:- 
              The Parvoviruses are composed of small capsid about 25nm 
in diameter and genome (9). The genome consist of single stranded 
DNA which composed of 5600  nucleotides showing remarkably few 
differences among isolates with the exception of the sequences of 
two variants V9 and A6, which are of uncertain clinical significance  (9). 
In addition, this genome encodes only three proteins. The first type 
known as nonstructural protein (NS1), which arises from the single 
unspliced transcript on the left hand side of the genome, sub-serve 
multiple replicative functions, and is cytotoxic to host cells. (10)  
           The two other types are structural proteins: the viral protein 1 
(VP1) and viral protein 2 (VP2). Those two types arise from 
alternative splicing .The viral capsid contains mainly VP2 and five 
present of the capsid protein for VP1. The folding of proteins creates 
alpha-helical loops that appear on the surface of the assembled 
capsid, where the host’s immune system can recognize them as 
antigenic determinants. The region unique to VP1 is external to the 
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capsid itself and contains many linear epitopes recognized by 
neutralizing antibodies (10). 
              VP2 and VP1 are expressed in the bacterial, mammalian, 
insect cell. In mammalian and insect cell, the expression of VP2 can 
self – assemble in the absence of viral DNA to produce virus – like 
particles (VLP) that physically, antigenically, and immunogenic-ally 
similar to native visions. (10) 
1.4 Pathogenesis and infection:-  
1.4.1 Viral life cycle and Blood Group Preceptor:- 
            The life cycle of B19 includes binding of the virus to host cell 
receptors, internalization, translocation of the genome to the host 
nucleus, DNA replication, RNA transcription, assembly of capsid and 
packaging of the genome and finally cell lyses with release of the 
mature virions (11). 
          Parvovirus B19 was initially shown to agglutinate human red 
cells and this agglutinin may act as the host cell receptor on erythroid 
progenitor cells. So the hemagglutinin was identified as the glycolipid 
globoside and also known as the blood group P antigen, by using 
hemagglutination as a surrogate marker (12). 
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           Parvovirus B19 and B19 viral protein 2 (VP2) and VLP both 
bind directly to P antigen which is considered as B19 receptor. In 
addition, Individuals lack genetically an antigen, are naturally 
resistant to B19 infection. P antigen is expressed on erythroid 
progenitors. In addition, it is present on megakaryocytes, endothelial 
cells, and fetal myocytes (12)  
1.4.2 Pathogenesis and immune response:-  
             Specific immunoglobulin IgM and lgG antibodies are 
produced following experimental and natural B19 inflection. Infection 
leads to a biphasic clinical course. One week after intranasal 
inoculation with B19 virus in healthy adult volunteers, viremia was 
detected in seronegative individuals accompanied by a mild illness 
with pyrexia, malaise, myalgia, itching, and excretion of virus from the 
respiratory tract. Shortly after 17 to 18 days of infection, a second 
phase of symptoms commenced. Scientists had characterized 
symptoms as rash, itching, or arthralgia. Recovery involves 
production of lgM antibody 10 to 12 days post infection, coinciding 
with a peak in the virus level. IgM usually persists in serum samples 
for approximately three months. It might last also for several months 
(13). 
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              IgG antibodies are detectable in volunteers within two week 
after inoculation and presumably persist for life and protect against 
secondary infections. A great role in protection against infection can 
be played, when detecting IgA by using the natural naso-pharyngeal 
route (13). In healthy B19 infected individuals, the predominant 
immune response is humoral (14). The early antibody response 
consists of lgM. It is purposely directed against VP2 while the mature 
response is lgG as the major antibody subclass and VP1as the 
primary target. (14). 
             A cellular immune response to B19 has been much harder to 
detect, although it must be present to illicit the humoral response (15). 
Recent studies have suggested that individuals mount a classic Th1 
(T- helper1) response to the virus with capsid protein presented to 
CD4 T cells through class two molecules (16). 
            During viremia, number of reticulocytes fall to undetectable 
levels, recovering seven to ten days later and resulting in a temporary 
drop in hemoglobin of 1gm/dl (0.6 mmol/L) in a healthy person. 
Clinically non-significant lymphopenia, neutropenia, and 
thrombocytopenia occur six to ten days after inoculation. The 
infrequently reported fullminant thrombocytopenia associated with 
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B19 infection may consist of two types. In the first type, 
thrombocytopenia precedes the onset of rash due to bone morrow 
suppression while the second type is probably emolliated by 
immunologic mechanisms (17). 
            The pattern of clinical disease is strongly influenced by the 
hematological and immunological status of the host. In healthy hosts, 
B19 infection may cause a self-limiting sub-clinical erythroid aphasia 
followed by arthralgia or rash mediated by immune response. In 
patients suffering from diminished production or increased destruction 
of erythrocytes, the infection can result in a dramatic decrease of 
hemoglobin. This might lead to a plastic crisis where in immuno- 
compromised individuals would fail to eradicate virus thereby 
generating a state of chronic anemia (18). 
1.5 Epidemiology:- 
1.5.1 Prevalence and Incidence:-  
              Parvovirus B19 is a global and common infection pathogen 
in humans. The prevalence of IgG antibodies directed against B19 
ranges from two to 15 % in children 1 to 5 years old, 15 to 60% in 
children 6 to 9 years old, 30 to 60% in adult and more than 85 % in 
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the geriatric populations (19). Women of childbearing age show an 
annual sero-conversion rate of 1.5 %. Although antibody is prevalent 
in the general population, viremia or presence of viral DNA is 
rare .The frequency of B19 viremia in voluntary blood donors has 
been estimated at rates of 1:167 to 1:35,000(19). 
1.5.2 Seasonal changes and contagiousness:- 
             Peak incidence of Erythema Infectiosum shows seasonal 
variations, occurring mainly during the months of late winter and early 
spring. Rates of infection may rise to an epidemic level ever 3 –4 
years, which is then reflected in the community by an increased 
number of children with Erythema Infectiosum, or where applicable 
transient aplastic crisis. 
            Secondary spread to seronegative contact is very common. In 
school or household settings, the secondary attack rate during 
epidemics of Erythema Infectiosum is about 50 % in susceptible 
children and 20 to 30 % in susceptible teachers (20). A part from 
teachers, the highest  
           Occupational risk of infection is generally found in people in 
close contact with children, such as day care workers (9%) and 
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homemakers (9%) while women working in other setting have  
reduced risk (4%) (20). 
1.5.3 Transmission:-  
            Transmission of infection occurs via the respiratory routes, 
through blood-derived products administered parenterally and 
vertically from mother to fetus. B19 – specific DNA has been detected 
in respiratory secretions at the time of viremia, suggesting that virus 
is generally spread in the community by a respiratory route. The 
case-to-case interval is 6 to 11 days irrespective of the type of B19 
related disease. (21) 
           Vertical transmission occurs in one – third of cases involving 
serologically confirmed primary maternal infection. Nosocomial  
transmission has been described infrequently. Transmission among 
staff in laboratories handling nave virus has been reported also (22). 
The risk of infection using single donor blood product is reported. B19 
has been transmitted by clotting factors specially VIII and IX. The 
sero-prevalence among hemophilic is about 90% with correlation to 
the amount of clotting factors received. B19 may infrequently 
transmitted by bone marrow and blood derived products such as 
platelets, intravenous immunoglobulin and fibrin products. Parvovirus 
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B19 infection and sero-conversion have been observed in patients 
after receiving solvent or detergent – treated plasma units (23).  
1.6 Diagnosis of B19:- 
             The diagnosis of parvovirus B19 is determined by 
cytopathology or detection of B19 virus or detection of antibodies.  
1.6.1 Diagnostic cytopathology:- 
              Although the presence of giant pronormoblasts in either 
bone marrow or peripheral blood is suggestive of B19 infection , their 
presence or absence should not be used alone to make a diagnosis 
of B19 infection(24). 
1.6.2 Detection of B19 virus  
            This is usually detected by isolation of viral DNA by direct 
hybridization or Polymerase Chain Reaction (PCR). Direct 
hybridization usually is found as a slot blot or dot blot format, 
generally employs an almost-full-length viral DNA probe labeled with 
p32, digoxigenin, or biotin to bind to DNA in clinical specimens. The 
hybridization assay will detect all known variants of B19 but lower 
levels of viremia induced by B19 infection will be missed. (25). 
            The advent of PCR has greatly increased the sensitivity of 
DNA detection in serum and tissue sample. DNA may be detected for 
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extended periods in serum, synovial membranes, and bone marrow 
even in healthy individuals. Therefore, the presence of low levels of 
B19 DNA alone is not used to diagnose acute B19 infection (26).  
1.6.3 Detection of Antibodies: 
              IgM capture assays will reliably detect a current or recent 
infection in immuno- competent persons, more than 85% of patients 
with Erythma Infectiosum or aplastic crisis due to B19 exhibit specific 
IgM, and these antibodies will remain detectable for two to three 
months following infection. IgG capture an assay is usually present 
and persist for life. Sequential sera may show a decline in lgG titer, 
but detection of IgG is generally not useful for diagnosis of acute 
infection, apart from detecting a sero-conversion in immuno-
compromised patients, who may not be able to produce lgM (27).  
1.6.4 Detection of NSI – specific antibodies: 
              The significance of detecting NSI-specific IgG that these 
antibodies were suggested to be associated with an altered course of 
disease (28). Studies showed that NSI-specific antibodies are primary 
found in-patient with arthritis or persistent infection (29). It is believed 
that prolonged viremia may lead to infection of cells outside the 
erythroid lineage in which gene expression shifts towards the 
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preferential transcription of the NSI gene rather than the VP1 and 
VP2 genes (28). Most of the studies find that irrespective of the 
underlying disease , NSI – specific-IgG appears late in infection more 
than six weeks  and the NSI antibody test may be used to exclude 
very recent infections in patients with an otherwise unclear serology 
( 30). 
1.7 Clinical aspect of parvovirus B19 infection: 
            The spectrum of the disease caused by parvovirus B19 varies 
according to the hematological and immunological status of the 
individual. 
1.7.1 Infection in the healthy Host: 
1.7.1.1 Asymptomatic infection: 
            Subclinical B19 infection is a common finding in both children 
and adult. Twenty five percent of infected persons had no recollection 
of specific symptoms and fewer than half of lgM positive women show 
signs of rash or arthralgia (31). Asymptomatic sero conversion 
following recent transfusion in patients with hemolytic anemia 
suggests that symptoms may be masked by transfusion of 
erythrocytes with a larger life span than the defective erythrocytes of 
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the host (32). In some cases, non – specific symptoms 
indistinguishable from the common flu may be noted (31). 
1.7.1.2 Erythema Infectiosum:  
              Also referred to as (slapped cheeks) disease or fifth disease, 
is the most prevalent manifestation of infection in children (33). 
Prodromal symptoms often go unnoticed but may include fever, 
coryza, headache, and nausea. Erythema Infectiosum is 
characterized by a facial Erythema of medium intensity involving the 
cheeks but with relative circumoral pallor slapped cheek appearance 
beginning 18 days after infection. A second stage consisting of rash 
involving the trunk and limbs occur 1 to 4 days later. The rash is rare 
in children especially those with aplastic crisis, this may be due to 
prolonged viremia and lack of IgM. In addition, patients with aplastic 
crisis often receive blood transfusion, so any developed rash may be 
attributed to transfusion rash. The rash is frequently lacy or reticular 
and consists of pink maculae that usually undergo a central fading, 
which causes the rash to take on a festooned appearance. The rash 
may be transient or recurrent and fluctuations of intensity can be 
linked to environmental factors such as exposure to sunlight and heat. 
It may associate with itching, vesicles, and scaly dermatitis (33).  
 34
1.7.1.3 Arthropathy: 
               In children with Erythema Infectiosum the incidence of 
arthralgia is approximately 10% or less while 19 % of children with 
recent – onset arthritis showed incidence of recent B19 infection. 
Among the latter persistent arthritis from two – three months, which 
would fulfill criteria for the diagnosis of juvenile rheumatoid arthritis 
was observed (34). In contrast, arthralgia and arthritis are the most 
common manifestations of primary B19 infection in adults, affecting 
60% of females and 30 % of males mean while dermal affection is 
less frequently and un- characteristic in adult’s population (35). The 
Arthropathy is immunologically mediated since the onset coincides 
with the appearance of circulating antibodies. Joint symptoms appear 
as an acute, moderately severe peripheral polyarthritis involving the 
metacarpophalangeal joint (75%), knees (65%), wrists (55%), and 
ankles (40%), showing no articular erosions (36). About 50% of 
patients with chronic B19 arthropathy meet the criteria for a diagnosis 
of Rheumatoid arthritis (35).  
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1.7.1.4 B19 infection in pregnancy: 
1.7.1.4.1 Hydrops fetalis 
            Parvovirus B19 infection causes non-hydrops fetalis. In 
addition, it has been found that fetal B19 infection may cause fetal or 
congenital anemia, abortion, or stillbirth or result in an asymptomatic 
self-limiting episode (37). 
            The pathogenesis of fetal damage appears to be similar to 
that of patients with aplastic crisis in which the erythrocytes have a 
reduced life span. Erythroblasts in the fetal liver exhibit signs of B19 
infection. This includes pathognomic cytopathology, viral DNA, and 
antigen (38).  
             In utero infection is persistent and characterized by severe 
anemia, high output cardiac failure, and death. Impaired circulation 
due to fetal myocarditis may contribute to the accumulation of fluids. 
B19 might also be associated with cases of non-Hydrops intrauterine 
fetal death (39). 
            The incidence of primary B19 infection during pregnancy has 
been estimated at 1 to 5 % and the subsequent transplacental 
transmission is 24 to 33% (40).  The risk of developing Hydrops 
following infection was reported in the past to be varying from (0 to 
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24%). According to recent studies the rate has probably lowered to (1 
to 1.6%) (41). 
               However, in pregnant women with confirmed primary 
infection, the overall risk of an abnormal outcome is approximately 5 
to 10% (40). The chance of an adverse fetal outcome after infection 
seems to be the greatest between 11 to 23 weeks of gestation, which 
correlates with hepatic period of hemopoietic activity (42). Fetal anemia 
can be corrected by intravenous transfusion of erythrocytes (43). The 
case fatality rate of hydrops fetalis may reach 50% but the transfusion 
has proven beneficial and lowered the mortality rate to 18 % (44). 
1.7.1.4.2 Congenital anemia 
                Hematological evaluation has revealed anemia in each of 
the examined B19 associated hydropic fetuses reported (45). Despite 
frequent reports of intrauterine B19 infection and hydrops, the risk of 
associated congenital anemia is low (46). Ordinarily, infection leads to 
one of two outcomes: lethal hydrops or a milder course of diseases in 
which the virus is eradicated and the virus effect ameliorated before 
term. However, the paucity of cases of congenital anemia may also 
reflect under diagnosis (47). 
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1.7.1.5Thrombocytopenia: 
             In children, most cases of idiopathic thrombocytopenic 
purpura are of acute onset and are often preceded by a specific viral 
infection (48).  
            Accordingly, B19 infection may result in Subclinical or 
overt thrombocytopenia. It mainly consists of a central and a 
peripheral type (49).  Thrombocytopenia of central origin is due to 
bone marrow suppression. The possible cytopathology effect is 
underlined by the finding that the NSI protein has been found to 
inhibit the megakaryocytic colony formation. This indicates tissue 
tropism of B19 beyond the erythroid progenitor cell and shows that 
viral proteins may be toxic to cell populations that are non-permissive 
for viral DNA (50). Destructive thrombocytopenia of peripheral origin 
may result from immunologically mediated anti-platelet antibody 
production with subsequent excessive platelet clearance in the 
reticuloendothelial  system (50). 
1.7.1.6 TEC and neutropenia: 
             Transient erythro-blastopenia of childhood (TEC) is a 
disorder of young children ages from three to four years, 
characterized by anemia, reticulocytopenia and decreased red blood 
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cell precursors in the bone marrow aspirate. TEC is the most 
common single cause of red cell aphasia in immunocompetent 
children and other cytopenias are increasingly being recognized in 
these patients (51). B19 has been a prime viral suspected in TEC 
patients due to its hematopoietic effects; hence it has been implicated 
in a number of cases. 
              Primary autoimmune neutropenia is caused by granulocyte 
specific autoantibodies. Primary autoimmune neutropenia occurs 
predominantly in infancy (52). The bone marrow of children was 
examined for B19 DNA. Results indicated that B19 infection might be 
a common cause of immune mediated neutropenia in childhood. 
However, more studies that are recent have not able to verify this (53). 
1.7.1.7 Neurological disease    
            Neurological symptoms associated with Erythma Infectiosum 
were reported in a few cases. Parvovirus B19 specific antibodies 
and/or DNA have been detected in blood and cerebrospinal fluid of 
fatal and non-fatal cases of encephalopathy, and aseptic meningitis 
(54). Neuropathy, complex regional pain syndrome, and neuralgic 
amyotrophy have been observed after B19 infection. Detection of 
1gM and DNA in cerebrospinal fluid seems to be a very rare event. 
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The mechanism for the neurological symptoms is unknown, but 
frequent rash or arthralgia is also present suggesting that the 
neuropathy may be immune mediated (55). 
1.7.1.8 Myocarditis 
            Histological examination and the finding of specific DNA in the 
nuclei of fatal myocytes demonstrate the cardiac tropism of B19, 
which may contribute to the development of hydrops fetalis (56). 
Clinically significant myocarditis and perimyocarditis have been 
diagnosed in a few children and adults (57). In addition, in pediatric 
cardiac transplant recipients, B19 infection has been noted to cause 
general disease as well as possible myocarditis. The finding of 
myocarditis is puzzling since B19 is thought to replicate only in rapidly 
dividing cells of hematopoietic origin, but this may be explained by 
the tissue distribution of the viral receptor (P antigen) involving 
myocytes or from immunological cross-reaction to epitopes shared 
between the virus and the myocardium (58). Considering that B19 is a 
common infectious agent, and that resulting myocarditis is currently 
believed to be a rare event, either the virus is only mildly cardiotropic 
or other unknown concerted factors are required to cause clinical 
disease (59).  
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1.7.1.9 Hepatitis 
             The role of B19 in hepatitis remains unclear. Although 
transient elevation of liver transaminases is not uncommon in B19 
infection, frank hepatitis associated with B19 infection has only rarely 
been reported, and in some of these cases, the diagnosis of B19 as 
the cause of the fullminant hepatitis has been questioned (60). 
            Studies of blood donors with raised transaminases do not 
suggest that B19 is a major cause of seronegative hepatitis (61). 
Similarly, B19 has been suggested as a possible causative agent of 
fullminant liver failure and associated aplastic anemia based on PCR 
studies (62).  
1.7.1.10 Putative associations 
            Parvovirus B19 has been suggested as the causative agent in 
a variety of clinical syndromes. Many of these studies are based on 
case reports or on detection of B19 DNA in tissues by PCR with no 
corresponding control group. 
          One investigation of children with Kawasaki disease found B19 
viremia in 67% (63). Other vasculitic and dermatologic syndromes 
caused by B19 include purpura, thrombotic renal graft 
microangiopathy, Reynaud’s phenomenon, Henoch-schönlein 
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purpura, polyarteritis nodosa, gloves and socks popular purpuric 
syndrome, dermatomyositis, and systemic lupus erythromatosus (64). 
Severe pneumonia, conjunctivitis, Behcet’s disease, idiopathic 
collapsing glomerulopathy, chronic autoimmune thrombocytopenia or 
neutropenia and a cute glumerulonephritis have also been suggested 
as possible manifestation of B19 infection (65). 
1.7.2 Infection in immuno-deficient host 
1.7.2.1 Chronic pure red cell aphasia 
             In immunocompromized patient unable to mount a 
neutralized antibody response due to a persistent bone marrow 
insufficiency, B19 infection may cause chronic anemia. Predisposing 
conditions include nezelof’s syndrome, acute lymphocytic leukemia,  
acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic 
syndrome, Burkitt’s lymphoma, lymphoblastic lymphoma, 
myelodysplastic syndrome, astrocytoma, wilm’s tumor, HIV infection, 
SCID, bone marrow transplantation, organ transplantation, class 
switch defect, steroid and cancer chemotherapy treatment and defect 
antibody specificity and neutralization (66). 
              Patients have absent or low levels of specific antibodies, 
with persistent or recurrent viremia being detected (67). Clinical 
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hallmarks include fatigue and pallor while immune-mediated 
symptoms (rash and arthralgia) are generally not presents (68). 
Infection may serve as a prodrome of an underlying disease and 
anemia may promptly remit after immunoglobulin or antiviral 
chemotherapy (in HIV patient) (69). 
1.7.2.2 AIDS  
               In one initial study involving 50 patients with AIDS, no cases 
of viremia were identified. However, the prevalence of B19 induced 
anemia in HIV sero-positive patients may be underestimated (70). 
Accordingly, B19 DNA was detected by dot blot hybridization in sera 
from five of 30 (17%) HIV infected patients with hematocrite of less 
than 24 and 4 of 13(31%) Patients with hematocrite of less or equal 
20 suggested that B19 is a common cause of severe anemia in HIV 
infection. The presence of IgM to B19, the clinical circumstance under 
which anemia developed, and he marrow morphology were poor 
predictors of chronic B19 infection (70).  
1.7.2.3 Acute lymphocytic leukemia  
               Chronic B19 infection has been described in case reports of 
adult and pediatric patients with leukemia (71).  Children with leukemia 
share the chief age of B19 infections and may be particularly 
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vulnerable to the ill effects of B19 due to immunosuppression. In one 
study, 8% of B19-seronegative ALL patients serocoverted while on 
maintenance chemotherapy, and there was a cluster of cases 
coinciding with a well-established B19 epidemic (72). B19 infection was 
able to mimic a leukemic relapse or therapy-induced cytopenia and 
contributed to the development of chronic anemia and profound 
thrombocytopenia in the majority of infected individuals. Infrequently, 
isolated thrombocytopenia or transient pancytopenia preceding ALL 
has been observed (73). 
1.7.2.4 Virus-associated hemophagocytic syndrome 
              Virus hemophagocytic syndrome (VAHS) is characterized by 
historical hyperplasia, marked hemophagocytosis and cytopenia, in 
association with a systemic viral illness. VAHS is usually a benign 
self-limiting illness in which histiocytic proliferation is reversible. 
 B19 infection has been detected in cases of hematophagocytosis 
syndrome among children and adults (74).  
 1.7.3 Infection in-patient with increased Red cell Turnover: 
     Transient aplastic crisis: 
                 It is a brief self-limited episode of pure red cell aphasia and 
was originally described in-patient with hemolytic anemia. However, 
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any person suffering from decreased red cell production or increased 
destruction or loss will be in danger of developing aplastic crisis 
following B19 infection. Cessation of the production of erythrocytes 
for 10 to 15 days, as seen during infection in healthy individuals, will 
lead in hemolytic patients to a marked drop in hemoglobin due to the 
underlying decrease in red cell survival in these patients (75). 
               Hemoglobinopathies per se do not predispose patients to 
infection with parvovirus B19.In one study; it was shown that the 
prevalence of antibody to the virus is equal in patients with 
Hemoglobinopathies and normal control (76). In other study, it was 
shown that patients with sickle cell anemia that had transient a plastic 
crisis, 70% had prior parvovirus B19 infection (77). In the study of 
Jamaican patients with sickle cell anemia, all cases of transient a 
plastic crisis were related to recent parvovirus infection(78). 
            Viremia is present in transient a plastic crisis, and red cell 
production resumes after antiviral antibodies that clear the infection 
have been produced. Although erythrocytes are predominantly 
affected with presentation, often pure red cell aphasia, concurrent 
thrombocytopenia, pancytopenia are found infrequently (79). While the 
anemia may be lethal, the plastic crisis itself usually terminated by the 
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appearance of specific antibodies and thus rarely lasts for more than 
two weeks. In children with hemoglobinopathies, 70 to 80 % of 
aplastic crisis are caused by B19 infection which manifested by pallor, 
weakness, and lethargy (80). The annual incidence is one to five%, 
predominantly affecting children and representing a unique event in 
life (80).       
1.8 Management of B19 infection  
                In the most cases, Erythema Infectiosum requires no 
treatment, while some patients with B19 induced arthralgia may need 
symptomatic treatment (i.e., anti – inflammatory drugs) (81). In cases 
of transient aplastic crisis caused by B19, prognosis is excellent once 
satisfactory hemoglobin concentration is obtained by erythrocyte 
transfusion. B 19 infection in pregnant seronegative women should 
be monitored by weekly ultrasound examination, and cordocentesis 
and intrauterine transfusions are effective in lowering the mortality in 
cases of hydrops fetalis. Effective therapy of persistent B19 infection 
(pure red cell aplasia) consists of infusion of immunoglobulin (0 – 4 g/ 
kg / day for 5 days or 1g/ kg/ day for 2 – 3 day), which is a good 
source of neutralizing antibodies. This treatment is usually 
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ameliorative and often curative leading to a marked increase in 
reticulocytes count and corresponding rise in hemoglobin (81). 
1.8.1 Vaccine development   
                Effective vaccines are available for animal Parvoviruses. 
The recombinant immunogen that was developed as a vaccine for the 
human lacks DNA and is therefore non-infectious. Empty capsid have 
been engineered to over express the highly immunogenic VP, and a 
single dose of 2 – 5 ug of empty capsid elicited neutralizing antibody 
responses in normal volunteers (82). As with many vaccines, 
commercial interest rather than lack of efficacy or safety has limited 
the development of parvovirus B19 vaccine. Such a vaccine could 
prevent transient aplastic crisis in patients with sickle cell disease or 
other hemolytic anemias and pure red cell aplasia in some 
immunodeficiency persons as well as hydrops fetalis if seronegative 
women were inoculated early in pregnancy (82).       
1.9  Role of parvovirus B19 in Hemoglobinopathies 
 1.9.1 Definition of Hemoglobinopathies:-       
            These clinical disorders result from abnormalities of the 
goblin genes, and they comprise a diverse group of hematological 
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diseases. The nucleotides of these genes may be substituted, 
deleted, or inserted in to goblin gene DNA. These disorders include 
sickle cell diseases: (sickle cell anemia, sickle cell trait, HbS in 
association with abnormal hemoglobin e.g. SC, SD, S O arab disease) 
and Thalassemia syndromes: (Thalassemia major and alpha 
Thalassemia) (83). 
1.9.2 Sickle cell disease: 
1.9.2.1 Definition of Sickle cell disease: 
             Sickle cell disease is a hemoglobinopathy caused by a single 
base mutation of adenine to thymine, which results in substitution of 
valine amino acid for glutamic acid at the sixth codon of the B-globin 
(83).  
1.9.2.2 Geographic distribution of sickle cell anemia: 
           Sickle cell anemia occurs widely throughout Africa, part of Asia, 
the Arabian Peninsula and parts of Southern Europe. In Africa, there 
are two areas with very high frequencies of sickle cell anemia. These 
include Nigeria, Ghana, and the others Gabon, Zaire, eastern part of 
Saudi Arabia and parts of east central India (84). 
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          Archie baled in 1926 first reported sickle cell disease in the 
Sudan.  There are three foci of the disease, in the south (among 
Southern Nilotics up to 18%), in the west (among the Misseria tribes 
up to 30%) and in central Sudan in the Blue Nile province up to 16 %, 
among immigrants from western Sudan and West Africa (85). 
1.9.2.3 Pathogenesis of sickle cell disease  
            The association of heme plus two normal alpha - globin and 
two abnormal beta-globin chains, forms hemoglobin S. It carries 
oxygen normally but begins to form semisolid aggregate structures 
once oxygen is unloaded to the tissues. These hemoglobin S 
aggregates distort the red blood cells and cause them to lose their 
normal elasticity. At first, hemoglobin S retains its ability to return to 
its soluble form, and the cell can regain their elasticity upon re-
oxygenation. However, this process damages the red cell, and with 
repeated deoxygenating cycle, permanent red cell damages ensue. 
The resultant rigid cells are responsible for, or participate in, the 
vascular occlusion and tissue ischemia that is the basis for 
abnormalities typical of this disease (86). 
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1.9.2.4 Clinical Feature of SCD: 
             The clinical Manifestations sickle cell disease is extremely 
variable. The newborn infant is protected by the high level of fetal 
hemoglobin in the red cells during the first eight to ten weeks of life. 
As the level declines, the clinical manifestations appear, and the 
hematological manifestations of sickle cell disease are apparent by 
10 to 12 weeks of age (87). Patients of SCD may exhibit some or all of 
the symptoms described. 
1.9.2.4.1 Anemia: 
            The life span of sickle cells is only 15 – 20 days compared to 
120 days for the normal red cells. In addition, the repeated cycle of 
de-oxygenation and morphologic sickling can irreversibly damage the 
red cell membranes and results in hemolysis. Bone marrow increases 
red cell production but is unable to compensate for the rate of 
hemolysis. This results in moderate to severe anemia (88). Children of 
SCD exhibit few manifestation of anemia such as tachycardia and 
increase stroke volume, cardiomegally, evidence of increase bilirubin 
production which is manifested by scleral-icterus and or urobilinogen 
excretion (88). Anemia in children with SCD can be precipitated by 
many crisises. Diggs defined sickle cell crisis as any new syndrome 
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that develops rapidly in patients with SCD due to the inherited 
abnormality (89). Sickle cell crisis may be precipitated by infection, 
hypoxia, and exposure to extreme cold, dehydration, and acidosis, 
which includes: 
1.9.2.4.1.1   Aplastic crisis: 
                A plastic crisis of SCD is a sudden cessation of bone 
marrow activity manifested by absence of reticulocytes from the 
peripheral blood and rapidly falling of the hemoglobin level. 
Depression of erythropoisis is generally associated with B19; it is the 
most important cause of such crisis. Platelet and white blood cell 
count usually are normal (90).           
1.9.2.4.1.2  Sequestration crisis: 
             It is one of the causes of death in children with SCD. It results 
from acute entrapment of large amount of blood in spleen manifested 
by left upper quadrant pain, hypovolemic shock, cardiovascular 
failure  and massive splenomegally may develop rapidly. It is 
associated with reticulocytosis, thrombocytopenia, and granulocytosis 
(91). 
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1.9.2.4.1.3  Hemolytic crisis: 
            The red cell life span is shortened in all varieties of sickle cell 
diseases. It may suddenly further be reduced due to increase rate of 
hemolysis and this can be described as a hemolytic crisis. Such crisis 
is very rare and associated with jaundice, falling of hemoglobin and 
elevated of reticulocytes count. An increase level of jaundice is not 
necessarily an indication of increased hemolysis; other causes for 
jaundice such hepatitis, cirrhosis and gallstones should be sought (92). 
1.9.2.4.1.4  Vaso-Occlusive crisis: 
            It is the most common crisis, which occurs in patients with 
sickle cell disease. It results from a complex interaction between 
endothelium, plasma factors, leukocytes, and rigid sickled red cells 
leading to the obstruction of blood vessels. Tissue hypoxia and tissue 
death occurs, leading to local pain (93). Vaso-occlusive crisis can 
manifest as pain involving hands and feet “hand-foot syndrome” in 
the younger age children or may involve the shaft of long bone in 
older ones. Acute chest syndrome that is the major cause of death in 
adult, represent the second cause of hospitalization of children with 
sickle cell disease (92). Stroke is another form of this crisis and has a 
high recurrence rate. It is frequency about six to nine % and about 
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11% of the products have stroke before the age of 20 years old (93). 
Infraction of the system is very common and manifested by 
abdominal pain. Autosplenectomy occur at the age of six to eight 
years old due to scarring of spleen. Priapism is a form of Vaso-
occlusive crisis and common among young men. It’s defined as 
frequent brief episodes of painful erection lasting one to two hours 
and resolves spontaneously, if it persist for more than twelve hours  it 
becomes a medical emergency since it lead to impotence. The 
incidence of Priapism among patient with sickle cell disease is six 
percent compared to children in general population (93). 
1.9.2.4.2 Infection  
             It is the most common cause of death in patients with SCA. 
The increased incidence and severity are related to the defects in 
host immunity. 
  1.9.2.4.2.1 Spleen 
           The spleen has two immunological functions, which are 
clearance of particulate matter from the intravascular space, and 
antibody synthesis. Both functions are impaired in SCA, resulting to 
functional asplenia and the patients become susceptible to 
pneumococcal infections (94).  
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1.9.2.4.2.2  Serum factors:  
            In spite of normal or increase serum immunoglobulin in 
patients with sickle cell disease, it is deficient in heat labile opsonizing 
activity related to an abnormality of the properdin pathway, which is 
specific for the phagocytosis of  pneumococci (95). 
1.9.2.4.2.3  The white blood cells: 
              A study showed that there is chronic leucocytosis of SCD 
and in another study reported the abnormality of granulocytes. 
However, Patients with SCD are more susceptible to encapsulated 
respiratory bacteria particularly streptococcus pneumoniae and 
hemophilus influnezae  type B which have mortality rate about ten to 
thirty percent. Staphylococci and salmonella also contribute a major 
cause of morbidity among sicklers. In addition to that, Chlamydia and 
Mycoplasma are responsible for serious infections (96).  
1.9.2.4.3 Chronic organ damage  
  1.9.2.4.3.1  Growth 
                 In patient with SCD is little affected and the height may be 
subnormal in children and young adolescents but it catch up to 
become normal in late adolescents and adults (97). 
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              The onset of puberty is delayed with normal bone age in 
children less than four years of age, and delayed bone age in older 
children 12 – 19 yrs of age. Transient impairment of the gonadal 
function has been observed, and this may explain the delay in the 
sexual maturity (98). 
1.9.2.4.3.2 Cardio-vascular System: 
              Sporadic case reports of pathologic finding in patients dying 
of heart disease have suggested the presence of a specific 
cardiomyopathy where as other studies failed to prove that (99). 
1.9.2.4.3.3 The Renal System: 
           Hyposthenuria, hematuria, nephritic syndrome, and uremia are 
the major renal complications of SCD, and lead to hypertension, 
proteinuria, anemia, and renal failure (100).  
 1.9.2.4.3.4 The liver: 
           Affection of the liver and the biliary tract are common in SCD 
that lead to cholelithiasis, hepatic infraction and transfusion related 
hepatitis (101). 
         It was shown that children with gallstones had significantly low 
total hemoglobin and fetal hemoglobin and higher bilirubin 
concentration. Further analysis showed that the apparent effect of 
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hemoglobin and fetal hemoglobin concentration were secondary to 
their relationship with bilirubin concentration (101). 
 1.9.2.4.3.5 The Eyes: 
           Tortusosity and sacculations of the conjunctival vessels is 
seen in more than 90% of patients with SCD, and have no harmful 
effect on the eye. Non-proliferative retinopathy can occur and require 
no therapy. Proliferative retinopathy is a serious complication 
that .leads to vitreous hemorrhage and retinal detachment (102). 
1.9.2.4.3.6 The skeleton: 
           Skeletal changes in SCD are common, due to expansion of 
the marrow cavity and repeated bone infarctions. The vertebrae have 
become flattened with characteristic biconcave deformity known as 
“Codfish vertebrae” (103). 
1.9.2.4.3.7 The Pulmonary System: 
          Pulmonary involvement is a major cause of mortality beyond 
the age of two years. Its pathological processes include infection, 
pulmonary infarction, fat embolism, and acute pulmonary 
sequestration. However, the later play a minor role (104). 
 
 
 56
1.9.2.5 Diagnosis of sickle cell disease: 
            Diagnosis of SCD depends up on the confirmation of the 
presence of sickle hemoglobin, preferably Hemoglobin 
electrophoresis. 
1.9.2.5.1  sickling test: 
            It is a simple rapid method that includes the observation of 
sickling of red cells containing sickle hemoglobin microscopically 
under cover slip by suspending the cells in droplet of 2% solution of 
sodium metabisulfite (105). 
1.9.2.5.2 Solubility test: 
           This test depends on the low solubility of reduced sickle 
hemoglobin, which results in the development of turbidity after diluting 
the blood in normal saline. It is also used for differentiation between 
heterozygous and homozygous sickle cell carriers. This test not is 
used in infants before the age of six months since a negative result 
may be misleading and does not exclude the presence of low 
percentage of HbS (106).  
1.9.2.5.3 Hemoglobin Electrophoresis: 
           Hemoglobin electrophoresis using alkaline buffer on cellulose 
acetate paper is a reliable test for diagnosis of SCD. Sickle cell 
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anemia can be diagnosed at birth by subjecting card blood sample to 
electrophoresis. Chorionic villous biopsy has been used extensively 
to obtain fetal DNA for the diagnosis in the first trimester (107). 
1.9.2.6 Management of patients with SCD: 
1.9.2.6.1 General Measures: 
             These include effective general medical care and appropriate 
management of complications. Education about the disease, the 
chance of having another child with SCD, and the importance of 
antenatal diagnosis must be illustrated to the parents (108). Counseling 
the parents about the risk of infections, which  is highest among 
children with SCD, the importance of immunizations, and penicillin 
prophylaxis. In addition, detection of enlarging spleen, pallor and 
fever may be life saving. Patients with sickle cell disease should be 
immunized against hepatitis B, hemoglobin influenza type B, and 
pneumococci (109).  
1.9.2.6.2 Specific measures; 
1.9.2.6.2.1 Painful crisis: 
            Paracetamol is satisfactory in most cases but in severe cases, 
pethedine or morphine may be needed. Warming and rehydration of 
the patient is important (110). 
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1.9.2.6.2.2 Blood transfusion: 
          It is indicated in cases of aplastic crisis, cerebrovascular 
accident, evidence of acute hemolysis, and sequestration crisis. In 
addition to that, acute chest syndrome, Priapism, and hemoglobin 
concentration less than 6gm\dl need blood transfusion (111). 
1.9.2.6.2.3 Partial Exchange Transfusion: 
            The aim is to reduce the patient’s total abnormal hemoglobin 
to about 40% (112). It indicated in cerebro-vascular accident , severe 
Priapism , severe hematuria and severe epistaxis and in preparation 
for major surgery (113).     
 1.9.2.6.2.4 Hydroxy Urea: 
            High HbF concentrations reduce the severity of sickle cell 
disease by preventing the formation HbS polymers (114). Hydroxyl 
urea was considered to act solely by increasing HbF concentration, 
but further studies suggested that the related reduction in 
neutrophiles, monocytes, and reticulocytes might be clinically 
important (115). Hydroxy urea also raises the total hemoglobin 
concentration  slightly (116).  
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1.9.2.6.2.5 Bone Marrow Transplantation: 
                First, it was done in Europe for patients from Africa, on the 
assumption that the risks of disease in their countries of origin 
justified the hazards of transplantation. These patients did well and 
since that time, more patients have undergone transplantations in 
Europe and United States (117). In study done using 100 patients, 
more than 90% of patients with SCA who undergone BMT survived, 
70 to 85 % had event – free survival and 15 % have graft rejection(118).     
1.9.3. Thalassemia: 
1.9.3.1 Definition and pathophysiology 
              Are various inherited disorders of hemoglobin synthesis 
resulting from an alternation in the rate of globin chain production. A 
decrease in the rate of production of a certain globin chains (alpha, 
Beta, gamma, delta) implies HB synthesis and creates an imbalance 
with the other normally produced globin chains. Since two types of 
chains pair with each other to form normal HB, an excess of the 
normally produced type is present and accumulates in the cell as an 
unstable product leading to the destruction of the cell. This imbalance 
is the hallmark of all forms of the Thalassemia (119). 
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                 For this reason, most thalassemias are not considered 
hemoglobinopathies, because the globin chains are normal in the 
structure and the defect is limited to decreased rate of production of 
these normal chains (120). The type of thalassemia usually carries the 
name of the under produced chains. The reduction varies from a 
slight decrease to complete absence of production (119).  
1.9.3.2 Geographical distribution:  
              Thalassemia genes are remarkably wide spread, and these 
abnormalities are believed to be the most prevalent of all human 
genetic diseases (121). 15 million patients have clinically apparent 
thalassemia. Certain types of thalassemia are more common in 
specific parts of the world. Beta Thalassemia is common in 
Mediterranean countries as Greece, Italy, Spain, Cyprus, Malta, 
and Sardinia. It found commonly in North Africa, Middle East, 
India, and Eastern Europe. Alpha Thalassemia is more common in 
Southeast Asia, India, Middle East, and Africa (122). 
1.9.3.3 Classifications of Thalassemia syndromes:  
               The most important types in clinical practice are those 
affecting either alpha or beta chain synthesis. 
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 1.9.3.3.1 Alpha Thalassemia  
            Several forms of alpha thalassemia are known, the most 
common forms are: 
  1.9.3.3.1.1  Silent carrier alpha Thalassemia: 
           This is a common type of Subclinical thalassemia partially 
among African American (123). One of the Alpha genes is usually 
absent leaving only three or four genes. Patients are hematologically 
healthy except for occasional low RBC indices. Diagnosis cannot be 
confirmed by Hb electrophoresis, which is usually normal. Complete 
blood picture of patient that demonstrates hypochromia and 
microcytosis in the absence of any explanation is frequently evident 
for the presence of Thalassemia (124).  
1.9.3.3.1.2   Alpha Thalassemia  trait:  
         It is characterized by mild anemia and low RBCs indices. It’s 
due to deletion of two alpha genes on one chromosome 16 (aa/oo) or 
one from each chromosome (ao/ao) (125). It is common in south East 
Asia, India subcontinent and parts of Middle East. The ao/ao from is 
more common in black population (126). 
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1.9.3.3.1.3   Hemoglobin H disease: 
            This results from deletion or activation of 3 alpha globin genes 
(00/ a0) represents alpha thalassemia Intermedia, with mildly to 
moderately severe anemia, splenomegally, icterus, and abnormal red 
cell indices (127). 
1.9.3.3.1.4  Alpha thalassemia major: 
          This condition is the result of complete deletion of the alpha 
gene cluster on both copies of chromosome 16 (00/00) leading to the 
severe form of homozygous alpha thalassemia which is usually 
incompatible with life and results in hydrops fetalis unless intrauterine 
blood transfusion is given (128). 
1.9.3.3.2  Beta thalassemia:  
        The more common forms are: 
1.9.3.3.2.1  Silent carrier beta thalassemia: 
         Like silent alpha thalassemia, one the beta genes is usually 
absent leaving three of four genes. These patients have no 
symptoms except for possible low RBC indices (129). 
1.9.3.3.2.2  Beta Thalassemia Trait: 
        Patients have mild anemia abnormal red cell indices and 
abnormal Hb electrophoresis with elevation of Hb A2, HbF or both. 
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The production of beta chains from the abnormal allele varies from 
complete absence to variable degrees of deficiency (130). 
1.9.3.3.2.3  Thalassemia Intermedia: 
        This condition is due to a compound heterozygous state 
resulting in anemia of intermediate severity that does not require 
regular blood transfusions (131). 
1.9.3.3.2.4  Beta thalassemia associated with beta chain 
structural variant: 
        The most significant condition in this group of thalassemia 
syndrome is the HbE/ beta thalassemia which may vary in its clinical 
severity from as mild as thalassemia Intermedia to as severe as beta 
thalassemia major (132). 
1.9.3.3.2.5  Thalassemia major: 
           Thalassemia major which is known as Cooley anemia is 
characterized by transfusion dependent anemia, massive 
splenomegally, bone deformities, growth retardation, and peculiar 
faces in untreated individual (133).  
1.9.3.4 Clinical Manifestations of Thalassemia: 
          The clinical pictures of thalassemia vary according to the type 
of thalassemia.  
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             In most patients with thalassemia traits, no signs or 
symptoms are encountered. Rarely, patients with severe forms of the 
disease, manifest some pallor and slight icteric discoloration of the 
sclera with splenomegally leading to slight enlargement of the 
abdomen (134). 
           In alpha thalassemia, the hematological abnormalities are 
clearly evident in newborns with mild or moderate from the disease in 
contrast to the homozygous alpha thalassemia in which there is lethal 
clinical consequences and physical deformities encountered at the 
time of birth (135). 
          Patients with thalassemia minor rarely demonstrate any 
physical abnormalities. Since the anemia is never severe and in most 
instances, the Hb is not less than 9g/dl, pallor and splenomegally 
rarely observed (136). 
          In beta thalassemia, symptoms of anemia start early when the 
gamma chain production switched off and the beta chain fail to form 
in adequate numbers. These include extreme pallor, enlarged 
abdomen due to hepatosplenomgally, Complications of severe 
anemia manifested as intolerance to exercise, heart murmur, or even 
signs of heart failure (137). In addition, Beta thalassemia caused other 
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manifestations that due to the effects of the profound anemia, the 
byproducts of hemolysis, and the intramedullay and extramedullay 
expansion of the erythroid marrow progenitors (138). Patients exhibit 
indirect abnormalities of a number of organ systems. These include 
the accumulation of end – organ damage due to iron overload, either 
from blood transfusions or from accelerated iron turnover, blood 
borne infections, or progressive diversion of caloric resources to bone 
marrow expansion (138). These include: 
1.9.3.4.1 Skeletal Changes  
             Skeletal abnormalities are frequently lead to marked changes 
in the facial structure and body producing the characteristics 
“chipmunk faces,” “hair – on – end” appearance and delayed skeletal 
maturation. These changes are due largely to the expansion and 
invasion of erythroid bone marrow, which widen the marrow space, 
attenuate the cortex, and produce osteoporosis (139) 
 1.9.3.4.2 Growth: 
           Growth retardation frequently found in these children due to 
the diversion of caloric resources for erythropoisis and the effects of 
anemia. However, the adolescent growth spurt often delayed, even in 
children who are hyper-transfused, unless intensive iron chelation 
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therapy instituted early in life. Normal statue thus rarely attained, 
even in well – managed patients (140).  
           Primary and secondary characteristics of sexual development 
usually delayed for both boys and girls. Menarche is frequently 
delayed and there is increasing evidence that hypogonadism may be 
primarily due to iron over load in patients maintained on adequate 
transfusion regimen. However, zinc deficiency may also play a role 
(140). 
  1.9.3.4.3  Endocrine Systems:  
           Patients with beta thalassemia may demonstrate signs of 
endocrinology caused by iron deposits. Diabetes and thyroid or 
adrenal disorders have been described in these patients (141) 
1.9.3.4.4 - G.I.T System: 
1.9.3.4.4.1 Liver:  
          Hepatomegally is prominent early in the disease, due to 
increased red cell destruction as well as extramedullay erythropoisis 
in this organ. Later in the first decade of life, hepatomegally becomes 
fixed and not reducible either by blood transfusion or due to the 
development of cirrhosis secondary to increased iron deposition. 
Ultimately provoking fibrosis and end stage liver disease occurs (142). 
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liver changes consistent with viral hepatitis , both hepatitis B and C 
are frequent , even in children who have received little or no 
transfusion therapy   and this due to iron over load (143). 
1.9.3.4.4.2  Gall bladder: 
           The development of premature gallstone disease and biliary 
tract inflammation is the prominent feature of children with beta 
thalassemia. Tow thirds of these patients have multiple calcified 
bilirubin stones by the age of fifteen. Fortunately, true episodes of 
cholecystitis or cholangitis are rare. Thus, Gall bladder removal is 
rarely indicated in the absence of clear-cut symptoms (144). 
  1.9.3.4.4.3 The Spleen: 
           Massive splenomegally develops early in the course of the 
disease due to the increased red cell distribution and the presence of 
extramedullay hematopoiesis in that organ (145). Splenomegally is 
progressive and can produce characteristics symptoms such as early 
satiety and hypersplensim. Shortened survival of transfused red cells 
or progressive worsening of the anemia in non-transfused patients is 
indications for splenectomy (146). Before and after splenectomy, 
children with thalassemia suffer immune deficits as the result of 
premature loss of splenic function. This is either due to the iron 
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overload within spleen or to the engorgement of splenic 
reticuloendothelial cells both lead to risk of overwhelming sepsis (146). 
1.9.3.4.5 Renal systems: 
            The kidneys often enlarged in thalassemia that is due to 
presence of extramedullay hematopoiesis with dilated renal tubules. 
Because of the high rate of cellular turnover, the risk for development 
of hyperuricemia and gout nephropathy is encountered (147).  
 1.9.3.4.6 Cardiopulmonary complications:    
           Most patients have mild abnormalities of pulmonary functions, 
including restrictive and small airway, obstructive defects, 
hyperinflation, decreased maximal oxygen uptake, and abnormal 
anaerobic thresholds (148).  
           Cardiac abnormalities are a major feature of thalassemia. 
Cardiac malfunction, including congestive heart failure and fatal 
arrhythmias, are frequent causes of death. Cardiomegally and left 
ventricular dysfunction ensue in the untreated children leading to end 
stage cardiomyopathy due to iron overload (149).   
 1.9.3.4.7  Aplastic crisis: 
             Thalassemic children with B19 infection often developed life-
threatening drops in hematocrite with reticulocytes count of nearly 
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zero. This so-called aplastic crisis usually requires emergent 
transfusion support.            
1.9.3.5 Diagnosis of thalassemia: 
             Diagnosis of thalassemia is usually done by complete blood 
count, peripheral blood film examination, and hemoglobin 
electrophoresis. These usually are sufficient to reach the diagnosis 
(150). However there are others investigations done to show the effect 
of thalassemia on body systems such as iron studies , skeletal 
surveys and other imaging studies like chest x – ray , MRI , CT scan . 
ECG, eye examinations, hearing test, and liver and renal function test, 
all are usually done (151).  
1.9.3.5.1 Complete blood count: 
              The picture of complete blood count varies according to the 
type of thalassemia. In severe from the Hb level ranges from 2 – 8 
gm/dl with MCV and MCH are significantly low. The WBCs counts 
usually elevated. However, the platelet count is normal unless the 
spleen is markedly enlarged. Peripheral blood film examination 
reveals marked hypochromasia and microcytosis, polychromatophilic 
cells, basophilic stippling cell, and Heinz bodies in case of Hb H (152). 
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1.9.3.5.2 Hemoglobin electrophoresis: 
              Usually reveals an elevated HbF fraction, which distributed 
heterogeneously in the RBCs of patients with beta thalassemia, Hb H 
in patients with Hb H disease, and Hb Bart in newborns with alpha 
thalassemia trait. In beta – O thalassemia, no Hb A is usually present, 
only HbA2 and Hb F are found (153). 
1.9.3.5.3 Prenatal diagnosis: 
              Polymerase chain reaction (PCR) techniques have become 
available; several new methods are now in use to identify affected 
bodies or carrier individuals accurately and quickly. The DNA material 
is obtained by Chorionic villous sampling, and mutations that change 
restriction enzyme cutting sites can be identified (154).               
1.9.3.6 Management of Thalassemia: 
1.9.3.6.1 Non-specific treatment: 
1.9.3.6.1.1 Diet: 
             Patients with thalassemia should receive normal diet with 
attention to the following supplements folic acid, small doses of 
ascorbic acid (vit. c) and alpha tocopherol (vit.E). Iron should not be 
given, and foods riches in iron should be avoided .Drinking coffee or 
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tea has been encouraged since it decreases the absorption of iron in 
the gut (155). 
1.9.3.6.1.2 Activity: 
             Patients with well-controlled disease usually are fully active. 
However, those with anemia, heart failure, or massive splenomegally 
usually are restricted according to their tolerance (155).  
1.9.3.6.2 Specific Management: 
1.9.3.6.2.1 Medical care:  
             Vary according to the type of thalassemia. Counseling is 
indicated in all genetic disorders especially when the family is at risk 
of a severe form of disease that may be prevented. Patients with 
thalassemia trait do not require medical care or follow up after the 
initial diagnosis is made. Patients with severe thalassemia require 
medical treatment in the form of regular blood transfusions combined 
with Chelation  therapy. 
1.9.3.6.2.1.1 Blood Transfusions: 
           Regular blood transfusion combined with well – monitored 
chelation therapy has become the standard therapy, and drastically 
has charged the outlook for this population of patients (156). It has 
many benefits including reversal of the complications of anemia, 
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elimination of ineffective erythropoisis and its complications, 
allowance of normal or near normal growth and development, and 
extension of patient’s life span (156). Blood transfusion should be 
initiated at an early age when the child is symptomatic and after an 
initial period of observation to assess whether the child can maintain 
an acceptable level of Hb without transfusion. Like all patients who 
require long – term regular blood transfusions, thalassemia patients 
require pre-transfusion work up. This includes RBC phenotype, 
hepatitis B vaccination if needed, iron and folate levels also showed 
be measured. The major complications of blood transfusions are 
those related to transmission of infectious agents or the development 
of iron overload (157).   
1.9.3.6.2.1.2 Chelation therapy:  
             Not long ago, patient with thalassemia major who received 
only transfusion therapy were not able to survive beyond the 
adolescence, largely because of cardiac complications caused by 
iron toxicity (158). The introduction of chelating agents capable of 
removing excessive iron from the body has increased life expectancy 
dramatically; delay the onset of cardiac disease and in same patients 
even prevents its occurrence. The optimal time to initiate chelation 
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therapy is dictated by the amount of accumulated iron and its 
accessibility for chelation. This usually occurs after one – two years of 
transfusions. Severe toxicity may develop when the chelation started 
prematurely (159). Deferoxamine is a complex hydroxylamine with high 
affinity for iron. It targets the labile pool, the non-transferrin – blood 
iron (free pool) and the ferritin generated from reticuloendothelial iron. 
It must be administered parenterally. The Oral  chelating agent 
deferiprone ( L1 ) have comparable efficacy as deferoxamine with 
minimal adverse effect and better compliance, recently , combination 
of two iron chelators ( e.g. parenteral deferoxamine plus oral L1 ) 
have been demonstrated to produce additive and synergistic effects 
(160).     
1.9.3.6.2.2Surgical care: 
                The principal surgical procedure used for many patients 
with thalassemia is splenectomy. The spleen is containing a large 
amount of the labile nontoxic iron derived from sequestration of the 
released iron. In addition, it increases the RBC destruction and iron 
distribution. Several criteria are used to aid in the decision for 
splenectomy (161). Splenectomy may be beneficial in patients who 
require more than 200 – 250 ml / kg of RBCs per year to maintain an 
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Hb level at 10gm/dl. Pre-splenectomy immunization and post surgical 
prophylactic antibiotics have decreased the rates of post splenectomy 
infections especially with encapsulated organisms (161).  
1.10 Studies done worldwide about parvovirus B1 infection 
among hemoglobinopathies:       
1. In study done by Saarinen U M, Chorba TL et al; 1986 “Human 
Parvovirus B19-induced epidemic acute red cell aplasia in patients 
with hereditary hemolytic anemia showed that human parvovirus 
B19 was the etiologic agent in that large epidemic of life – 
threatening acute red cell aplasia in patients with hereditary 
hemolytic anemia ". (162) 
 2. In study done by Smith MA et al ; 1989 “ Parvovirus B19 
infection associated with reticulocytopenia and chronic 
autoimmune hemolytic anemia " showed the parvovirus B19 cause 
reticulocytopenia at presentation in autoimmune hemolytic 
anemia(163).  
3. In study done by Truscher Tetal, Baillod B, Holzer BR; 1991 
“The prevalence of human parvovirus B19 in sickle cell disease 
and healthy control.” In which 35 patients with SCA (HbSS) 
randomly chosen from a sickle cell clinic in rural south – west 
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Togo and 13 household members with normal hemoglobin type 
(HbAA) was studied. The study showed that Human parvovirus 
infection exists in West Africa and there is no evidence for 
increased seroprevalence in SCA. In addition, the HPV does 
not seem to trigger acute painful crisis in SCA and the specific 
HPV seropositivity increase in urban patients may be due to the 
differing transmission rates in urban and rural areas (164).  
4. In another study done by Rao SP, Miller ST, Cohen B J; 1992 
“ Transient aplastic crisis in patients with sickle cell disease" 
showed that approximately 70% of causes of transient aplastic 
crisis in patient with sickle cell disease were caused by acute 
parvovirus infection. Once detected, antibody parvovirus IgG 
antibodies remain detectable for several years. There was no 
evidence of chronic or recurrent B19 infection in patients with 
sickle cell disease (165). 
5.  In study done by Fabio S Aguiar et al ; 1992 “ Human parvovirus 
B19 infection in H/V – positive patients" showed that persistent 
infection causing anemia due to B19 infection is an infrequent finding 
in our H/V positive patients under drug therapy (166). 
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 6. In another study done by Zanella A, et al; 1995 “Transfusion – 
transmitted human parvovirus B19 infection in a thalassemic patient 
" . Showed that transmission of HPV B19 can be result by the 
transfusion of one red cell unit, and possible transient aplastic crisis 
can occur (167).  
7. In study done by Broun , K.T et al ; 2000 “ Hematological 
consequences of parvovirus B19 infection" showed that parvovirus 
B19 has a direct cytotoxic effect on erythroid progenitors in bone 
marrow with interruption of erythrocyte production, in individual with 
underlying hemolytic disorder B19 infection causes transient aplastic 
crisis (168).  
8. In study done by Iaguzhinskaia OE et al; 2001 “Diagnosis of 
parvovirus B19 infection in hematological patients with partial red cell 
aplasia of the bone marrow “. In which 108 patients with hemolytic 
anemia was conducted by using PCR and EIA for the diagnosis 
parvovirus B19 infection and it was found that  reliable diagnosis of 
parvovirus infection is possible only in simultaneous use of PCR and 
EIA (169). 
9. In study done by Wermelinger MC et al ; 2002 “ Detection of 
human parvovirus B19 infection : a study of 212 suspected cases in 
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the state of Rio Janeiro , Brazil and showed that parvovirus B19 
circulates in several regions of the state of Rio Janeiro (170).  
10. In study done by X H Qian et al ; 2002 “ aplastic anemia 
associated with parvovirus B19 infection " showed that parvovirus 
B19 infection might be associated with severe aplastic anemia (171).  
11. In study done by Badr , M – A ; 2002 “ Human parvovirus B19 
infection among patients with chronic blood disorders" showed that 
parvovirus B19 can be considered as one of the predisposing factors 
of hemolytic crisis in patients with chronic hemolytic disease (172).  
12. In study done by Zimmerman SA et al; 2003 “Subclinical 
parvovirus B19 infection in children with sickle cell anemia ’’ showed 
that  in the teen-age years, most pediatric patients with SCA have 
serologic evidence of pervious parvovirus B19 exposure. However, 
Subclinical parvovirus infection appears to be common in children 
with SCA, since most patients have no documented pervious 
transient aplastic crisis (173). 
13. In study done by Smith – Whitley K, et al. 2004 “ Epidemiology of human 
parvovirus B19 in children with sickle cell disease ’’ This study justify the 
development of HPV B19 prevention strategies to diminish the frequent and often 
severe complications associated with HPV  
B19 infections in patient with SCD (174).  
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Justification: 
1. Parvovirus B19 is the most important virus that is responsible for 70 – 
80 % of aplastic crisis in children with Hemoglobinopathies leading to 
serious complications. 
2. Parvovirus B19 commonly causes sub-clinical or asymptomatic 
infection so the majority of the cases are missed. 
3.  Reviewing Sudanese children with B19 will give us a better insight 
for clinical approach, diagnosis and management. 
4.  No study on Parvovirus B19 has been done in the Sudan. 
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Objectives: 
1.  To determine the seroprevalence of parvovirus B19 in children with 
Hemoglobinopathies. 
2.  To identify the co – relation between Parvovirus B19 virus and 
aplastic crisis in children with Hemoglobinopathies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 80
 
 
 
 
 
 
CHAPTER    TWO 
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Material and Methods 
2.1-Nature of the study: 
            Prospective, descriptive, comparative hospital based study. 
2.2-Study Area: 
           The study was conducted in pediatrics wards of all hospitals of the 
Khartoum state mainly: 
        Khartoum Children’s Emergency Hospital 
       Ahmed Gasim Hospital 
       Omdurman Hospital  
       Sickle cell clinic.  
2.3-Duration of the study: 
           The study was conducted from September-December 2004.  
2.4-Study Population: 
2.4.1-patients: 
            Children below 18 years who had diagnoses of  hemoglobinopathies, 
confirmed by hemoglobin electrophoresis and, presented to the study area. 
2.4.2- Control Group: 
          Children whose ages ranged from a month to 18 years with 
hemoglobin AA, who presented to the outpatients clinic with different 
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problems (eg.Gastroenteritis, pneumonia, malnutrition, and malaria) were 
included as the control group in the study.  
2.4.3-Inclusion Criteria: 
            Children aging between a month-18years, who were confirmed to 
have hemoglobinopathies by hemoglobin electrophoresis,  and presented to 
the study area with signs and symptoms of anemia. In addition, the study 
included patients who presented with signs and symptoms of anemia and 
hemoglobinopathies for the first time.  
2.4.4-Exclusion Criteria: 
           Children with hemoglobinopathies who received blood transfusion 
(less than six weeks) before the sample has been taken, or stopped the intake 
of folic acid tablets abruptly and presented with acute anemia, jaundiced 
patients, or whose parents refuse to participate in the study, were excluded 
from the study. 
2.5-Sample Size: 
            The number of patients that should be involved in the study is 193 
patients and control calculated according to the equation: 
n= z pq/d  
Where: 
n = sample size 
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z = statistical certainly (1.96 with 95% C I) 
p = the prevalence of parvovirus infection (0.05) 
q = 1- p 
d = degree of accuracy 
             Due to the expensive cost of parvovirus kits,  I could not complete 
the sample size to its optimal number (193 patients and control) and I took 
only 90 patients and control.  
             Ninety patients with hemoglobinopathies were included in this study, 
who presented to the study area during the study duration.     
            Random controls of ninety patients with hemoglobin AA were 
selected by simple randomization method who presented to the outpatients 
clinics of Khartoum Children’s Emergency Hospital with different problems.  
2.6-Ethical Consideration: 
             Verbal consent was obtained from the doctors who took care of the 
patients, parents and children with hemoglobinopathies. In addition, written 
consent was presented to all hospitals of the study area.  
 2.7-Study techniques and tools: 
2.7.1-Questionaire:  
          Detailed questionnaire was obtained from every child in the study 
group, which included personal, past, family, and drug histories. Clinical 
 84
examination was conducted which included  vital signs,  anthropometric 
measurement, systemic examinations of chest, cardiovascular, abdomen, 
musculoskeletal and genitourinary systems was obtained. 
2.7.2-Investigations: 
            Hemoglobin level and reticulocyte count was done for every child in 
the study population according to the standard methods.  
           Sickling test and hemoglobin electrophoresis was done for diagnosis 
and confirmation of -hemoglobinopathies. 
          Detection of the parvovirus antibodies IgG and IgM antibodies using 
enzyme-linked immunosorbent assay (ELISA) methods. 
2.7.2.1 Sampling: 
          Five ml of venous blood was collected from each confirmed 
hemoglobinopathic patient and divided in to two samples. Two ml of blood 
for hemoglobin level and reticulocytes count collected in K.EDITA 
containers and three ml in plain containers containing clots activators to 
facilitate the separation of the samples. The samples transported 
immediately to the laboratory where the three ml sample( centrifuged for 
separation of the serum, and  stored at -20 C to be used for detection of 
parvovirus antibodies IgG and IgM.)  and 2-ml sample for hemoglobin and 
reticulocyte  count measurement. 
 85
           Three ml of venous blood were collected from each control group 
patient for hemoglobin electrophoresis (Hb AA) together with five ml for Hb 
percentage, reticulocyte count, IgG and IgM antibodies detection.   
2.7.2.2-Detection of the parvovirus antibodies: 
2.7.2.2.1-Test Principle: 
              Solid phase enzyme-linked immunosorbent assay (ELISA) based on 
the sandwich principle.  The wells are coated with antigen. Specific 
antibodies of the samples binding to the antigen-coated wells are detected by 
a secondary enzyme conjugated antibody (E-AB) specific for human IgG 
and IgM. After the substrate reaction, the intensity of the color developed is 
proportional to the amount of IgG-IgM-specific antibodies detected. Results 
of samples can be    determined directly using the standard curve.  
2.7.2.2.2-Test Procedure: 
               Hundred ul of each standard, control, and diluted (1:1000) samples 
were pipette in to the respective wells of the Microtiter plate and incubated 
for an hour at 37 C. Then discarded the incubation solution (wash plate 3 x 
with 250 ul of diluted wash buffer and remove excess solution by tapping 
the inverted plate on a paper towel). After that pipette 100 ul of IgG or LgM 
Enzyme Conjugated in to each well, incubated for 30 minutes at 37 C and 
discarded the incubation solution again. Hundred ul of TMB Substrate 
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Solution were pipette into each well, incubated for 10 minutes at 18-25 C in 
dark room, and then the substrate reaction was stopped by adding 100 ul of 
TMB Stop Solution into each well. Lastly measurement of optical density 
with a photometer at 450nm (reference-wavelength: 600-650) within 15 
minutes after pipetting of the Stop Solution was done.  
2.7.2.2.3-Quantitative Calculation: 
                The obtained OD of the standards are plotted against their 
concentration on either semi-logarithmic graph paper or using an automated 
method. A good fit is provided with cubic spline, 4 Parameter Logisitcs or 
Logit-Log .For calculation of the standard curve, apply each signal of the 
standards and the concentration of the samples can be read directly from the 
standard curve.     
2.7.2.2.4-Interpretation of the Results: 
                Positive IgG results together with negative IgM values indicate an 
infection in the past. Positive IgM results together with negative or positive 
IgG values indicate a recent infection.                     
IgM concentrations around the cut off value together with undetectable or 
very low IgG values can be seen in an early stage of infection, which can be 
confirmed by measurement of an increase in IgM and IgG concentrations in 
a second sample after two weeks. Low IgM values together with medium or 
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high IgG concentrations indicate an infection about 1-2 months ago. This 
should be proven by a further sample taken 4-6 weeks later showing a still 
positive IgG but at that time a negative IgM value. Low or medium IgM 
values in combination with negative or low IgG values can either indicate a 
very recent parvovirus infection or in rare cases also indicate polyclonal 
antibody stimulation by another infection.  
2.8- Data Analysis and Statistics: 
                  All data collected from each child were coded for subsequent 
computer processing and analysis using SPSS (Statistical Package for Social 
Science). Frequencies and descriptive statistics were obtained for all 
variables. Chi-square tests were computed for selected variables. The level 
of significance was taken as less than 0.05 using Yates corrected tests.  
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RESULTS 
3.1 Sociodemographic characteristics of children of the 
study: 
3.1.1. Age distribution of children of the study 
population: 
                 Fig (1) shows the distribution of children of the study 
population according to their ages.  The majority of children, 
40(44.4%) patients with hemoglobinopathies, were those whose ages 
are less than five years, 32 (35.6%)  patients were between 5 and 
less than 10 years, nine(10%) patient were between 10 to less than 
15 years old. Finally, children between 15 to 18 years old were nine 
patients making up to 10% of patients. 
             The distribution of control group of 90 patients of children 
with similar age groups results were as followed: - The majority of 
patients where between 5 and less than 10 years old accounts 34 
children (37.8%). The number of children with age less than 5 year 
constituted 26 children (28.9%). Children with ages between 10 and 
less than 15 year were 20 children (22.2%). Lastly, children with ages 
from 15 and less than 18 were 10 patients (11.1%).   
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3.1.2 Gender distribution of children of the study group:   
              Fig (2) shows the Gender distribution of children of the study 
population of 180 children. A number of 46 male patients had 
hemoglobinopathies, which constitutes 51.1% of patients. The female 
patients were found to be 44 (48.9%) patients. The control group 
survey resulted in 57 males (63.3%) and 33 females (36.7). 
3.1.3 Residence of children of the study population:  
             Fig (3) shows the residence of children of study population of 
about 180 patients. A number of 77 (85.6%) of hemoglobinopathic 
patients resided in urban areas. About eight patients (8.9%) were 
dwelling in rural areas. In addition, five (5.6%) patients resided in sub-
urban areas. In control group, 82 (91.1%) patients resided in urban 
areas. Only five children dwelled in rural areas (5.6%) and about 
three (3.3 %) inhabited sub-urban areas. 
 
 
 
 91
 92
 
 
 
 93
 
 
 94
 
3.1.4 Tribal distribution:  
                Fig (4) shows the tribal distribution of children of the study 
population (180 patients).  
               The majority of patients with hemoglobinopathies were from 
Mesyeria tribe 28(31%). About 19 (21%) patients were from Selehaab, 
and ten (11.1%) patients were from Hawosa. Five (5.5%) were from 
Falatah tribe (36.7%), seven(7.8%) patients of Taayishah, eight 
(8.9%) patients of Barno, five (5.5%) patients of Fadynia, and eight 
(8.9%) of Magarba tribe.  
             The tribes of patients of the control group are Messiria 
18(20%), Mahas 17(18.9%), Danagla 15(16.7%), Selehab 14(15.6%), 
and Halfaween 12 (13.3%). Falata seven (7.8%), Barno four (4.4%), 
and Hawsa three (3.3%). 
              Fig (5) shows Seventy-eight (86.7 %) of patients with 
hemoglobinopathies were relatives, while 12(13.3%) patients were 
not relatives. In contrast to the control group 69(76.7%) were relatives, 
and 31 (33.3%) are not relatives. 
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             Fig (6) shows the family history of hemoglobinopathies 
62(68.9%) patients had family history while 28(31.1%) with no family 
history. 
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Fig (4) 
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Fig (5) 
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Fig (6) 
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3.1.5 Educational level: 
              Fig (7) shows the standard of education of children in the 
study group. The majority of patients 38(42.2%) with 
hemoglobinopathies were before preschool age. A  number of 
26(28.9%) patients  were of primary school , 15( 16.7%)  were 
illiterate (off school) patients , five(5.6%) patients were of preschool , 
three(3.3%) patients were of Quaranic education , and three(3.3%) 
patients were of secondary education level . In the control group, the 
majority were of primary school 44(48.9%) patients. A number of 
12(13.3%) were of preschool, 17(18.9%) were before preschool age, 
three (3.3%) were illiterate (off school), 13(14.4%) patients were of 
secondary school, and one patient (1.1%) was of Quaranic education. 
                 Fig (8) shows the father’ education, the majority of fathers 
of hemoglobinopathic children were illiterate 34(37.8%). 24(26.7 %) 
were of primary school education, 16(17.8%) were of secondary 
school education, 14(15.6%) were of intermediate education and two 
(2.2%) were of university education. In contrast to the control group, 
the majority of fathers 29(32.2%) were of high secondary school 
education, 22(24.4%) were of primary school education, 22(24.4%) 
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were of intermediate school education, nine (10%) were of university 
education and eight (8.9%) were illiterate.  
                  Fig (9) shows the mother’ education, most mothers 
54(60%) of hemoglobinopathic children were illiterate. A number of 
16 mothers (17.8%) were of intermediate education, 13 (14.4%) were 
of primary school education, five (5.6%) were of high secondary 
education and two mothers only (2.2%) were with university 
education. In control group, also most mothers 42(46.7%) were 
illiterate, 26(28.9%) mothers were of primary school education, 13 
(14.4%) were of intermediate school education, and nine (10%) 
mothers were of high secondary education. 
3.1.6   Parents’ Occupation: 
                  Fig (10) shows parents occupation, most of the fathers 
with hemoglobinopathic children were laborers 65(72.2%). A number 
of six (6.7%) were skilled laborers, ten (11.1%) were employees, 
seven (7.8%) are running small business, and two (2.2 %) patients 
were professional. In contrast to the fathers’ occupations of the 
control group test, 32 (35.6%) were laborers, 28(31.1%) were 
employees, 20(22.2%) were skilled laborer, nine (10%) were 
professional, and only one (1.1 %) run small business. 
 101
                Fig (11) shows Mother’s occupations of patients with 
hemoglobinopathies found as follows: 65(72.2 %) housewives, 22 
(24.4 %) were running small business, two were professional (2.2 %), 
and another one (1.1 %) laborer. Mother’s occupation of control 
group were 76(85.4 %) housewives, 11 (12. 2 %) were running small 
business, one (1.1%) employee, and only one (1.1 %) labor (table 2). 
3.1.7   The type of housing and socioeconomic status:  
                              Fig (12) shows the type of housing in the study 
group, 53(58.9 %) of patients with hemoglobinopathies reside in 
houses made of mud, 28(31.1 %) were made of brick and nine (10%) 
were huts. In the control group, 48 (53.3 %) were made of mud, 32 
(35 .6 %) were made brick and 10 (11.1 %) were huts. 
                Fig (13) shows the socioeconomic status of population in 
the study group, patients were categorized in three groups. Firstly, 
patients of moderate socioeconomic status were 25 (27.8%). A 
number of 65 patients (72.2 %) were of law socioeconomic status and 
none is of high socioeconomic status. In the control group, 32 
patients (35.6 %) were of moderate socioeconomic status, 58 
patients (64.4 %) were of law socioeconomic status, and none of high 
socioeconomic status.   
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Fig (7) 
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Fig (8) 
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Fig (9) 
 
 
 
 105
Fig (10) 
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Fig (11) 
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Fig (12) 
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Fig (13) 
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3.2 Age at presentation and initial diagnosis of      
Hemoglobinopathies: 
                     Fig(14) shows the age of presentation for patients with 
hemoglobinopathies which was divided to three groups as follows: 
children whose ages from 1 month to less than 6 months, accounted 
26 (28 .9 %) patients. 48(53.3) were between 6 months to less than a 
year, and 16 (17.8%) patients were more than 12 months.. 
                    Fig (15) shows the age of diagnosis of 
hemoglobinopathies. Patients were classified into three categories. 
Firstly, from a month to less than 6 months were 22 children (24.4 %). 
Children from 6 months and less than 24 month were 64 (71.1 %) 
and those with ages more than 24 month were 4 (4.4 %) patients. 
3.3   Type of Hemoglobinopathies:. 
                         Fig (16) shows the type of hemoglobinopathies, 75 
(83.3 %) patients of sickle cell anemia, two (2.2 %) patients were of 
S-C type and 13 (14.4 %) patients were with thalassemia. 
3.4 History of hospitalization in study population: 
                 Table (1) shows the hospitalization among patients in the 
study group, 61(67.8%) hemoglobinopathic patients were admitted 
less than 5 times. Seventeen patients (18.9 %) were admitted up to 
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10 times, and 12 (13.3 %) patients were admitted more than 10 times. 
In contrast to the patients of control group, 88 patients (97.8 %) 
admitted were less than six times, and two patients only (2.2 %) were 
admitted less than 10 times 
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Fig (14) 
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Fig (15) 
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Fig (16) 
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Table (1): Number of hospital admissions among children 
                  In the study population                      
NO. of hospital admission Patient                             Control    
 
No hospital admission            ----------- ---------- 
 
1 – 5 times                     61(67.8%) 88(97.8%) 
 
6 – 10 times                                 17(18.9%)                        2(2.2%) 
 
   > 10 times              12(13.3%)          -------- 
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3.5 Risk factors in the study population: 
3.5.1 Housing condition: 
.            Table (1) shows housing condition in the study group, 23 
(25.6%) of patients with hemoglobinopathies had good housing 
condition, while 67 (74.4%) had bad housing condition. In control 
group, 30 (33.3%) patients had good housing condition, and 60 
(66.7%) had bad housing condition.  
3.5.2   Number of blood transfusion in the study group:                
                    Fig (17) shows the history of blood transfusion or blood 
driven product, transfusion (plasma, immunoglobulin, factors) among 
patients with hemoglobinopathies lasts more than 6 wks. The majority 
of 30 patients were received up to 5 times blood transfusion (33.3 %), 
27 patients (30 %) were received up to 10 times, 13 patients (14.4 %) 
were received more than 10 times, and 20 (22.2 %) patients had no 
history of blood transfusion. While in the control group, 73 patients 
(81.1%) has no history of blood transfusion, and 17 patients (18.9 %) 
were received blood transfusion up to 4 times. No medical history of 
blood derived product transfusion was recorded among patients in 
both study groups (table1) 
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3.5.3   History of upper respiratory infection:.  
              Table (1) shows all patients with in the study population had 
history of upper respiratory infection.  
3.6   History of skin rash, arthralgia  & palpitation: 
                      Skin rash affected 51(56.7 %) patients with 
hemoglobinopathies and 33 (36.7 %) patients of the control group. 
Arthralgia or arthritis found in almost all patients with 
hemoglobinopathies while 22 (24.4 %) in patients of control group. 
Palpitation was found among 36 (40 %) patients with 
hemoglobinopathies and 20(22.2 %) patient of the control group. 
3.7   History of operation 
                    Four (4.4%) patients had history of splenectomy while 
two (2.2 %) patients of control group had history of appendecectomy.  
3.8   History of folic supplementation:  
                 Administration of folic acid tabs prophylaxis, almost all 
patients with hemoglobinopathies were on regular folic acid tabs 
intake.  
3.9   History of Desfroxamine administration:  
                 Administration of desfroxamine among thalassemic 
patients, there was only one patient on regular desfroxamine therapy. 
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Table (2)    Risk factors in the study population   
Risk factor Patients Control 
 
1-Housing condition:  
.  Good                           23(25.6%)                        30(33.3%)
.  Bad                                67(74.4%)                     60(66.7%) 
2-Number of blood transfusion: 
.No history of blood       20(22.2%)                    73(81.1%) 
transfusion 
.1–4 times                       30(33.3%)                      17(18.9%) 
5 – 10 times                     27(30%)                           --------- 
.  > 10 times                    13(14.4%)                         --------- 
 
3- History of upper           
Respirtory infection        90(100%)                      90(100%) 
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Fig (17) 
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3.10 Presenting complains:  
                 Table (2) shows that, 42 patients (46.7 %) with 
hemoglobinopathies had no complain (Asymptomatic), they came in 
the referred clinic for follow up, 48(63.3%) patients presented with 
fatigability and malaise, 15(16.7%) with palpitation, six(6.7%) with 
right hypochondrial pain, 15(16.7%) patients with arthralgia and 
18(20%) patients with joint swelling. In control group, 46 (51.1%) 
patients presented with fatigability and malaise, two (2.2%) patients 
with palpitation, two (2.2%) patients with right hypochondriac pain, 
11(12.2%) with arthralgia and two (2.2%) patients presented with skin 
rash. 
3.11 Physical examination: 
                     Fig (18) shows the weight of the patients with 
hemoglobinopathies 75 (83.3%) were below the third centile, While 
39 (43.3%) patients of the control group below the third centile. 
                    Fig (19) shows the height of patients, 45 (50%) of 
hemoglobinopathic patients were below third centile while, 27 
patients (30%) of the control group were below the third centile. 
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                 In contrast to the head circumference, 10 (11.1%) patients 
with hemoglobinopathies were below third centile and six (6.7 %) 
patients of the control group were below third centile.  
                     Table (3) Shows the important clinical findings in 
patients with hemoglobinopathies, 65 patients (72.2 %) were pale, 
13(14.4%) had frontal bossing and maxillary prominence, 80(88.9%) 
patients had hepatomegally, 28(31.1%) had splenomegally, 11(12.2%) 
had hand-foot syndrome, ten (11.1%) had bone involvement and 
seven (7.8%) patients presented with arthritis. Two (2.2%) patients 
were presented with signs of heart failure (tachycardia, gallop rhythm. 
tachypnea, Basal crepitations and tender hepatomegally). In the 
control group, 11(12.2%) patients were pale, 15(16.7%) had 
hepatomegally, ten (11.1%) patients had splenomegally, seven (7.8%) 
had arthritis.  
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Table (3): Clinical symptoms in study population  
 
Symptoms Patients Control 
 
Asymptomatic  42(46.7%)                        ----------- 
Malaise                            48(63.3%)                       46(51.1%)
 
Palpitation                        15(16.7%)                          2(2.2%) 
    
Right hypochondrial           6(6.7%)                             2(2.2%)  
pain 
 
Skin rash                          -----------                            2(2.2%) 
 
Joint pain                          15(16.7%)                      11(12.2%)
 
 
Joint swelling                    18(20%)                           -------- 
 
 
 
 122
Fig (18) 
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Fig (19) 
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Table (4)      clinical Signs in study population 
 
Signs Patients Control
Pallor                                  65(72.2%)                   11(12.2%)   
 
Frontal bossing                    13(14.4%)                      --------- 
 
Maxillary prominence           13(14.4%)                      -------- 
 
Hepatomegly                        80(88.9%)                       ------- 
 
Splenomegly                       28(31.1%)                         -------- 
 
Hand-foot syndrome          11(12.2%)                         --------- 
 
Bone involvement              10(11.1%)                        -------- 
 
 Arthritis                               7(7.8%)                         7(7.8%) 
 
 
Signs of heart failure: 
 
.  Tachycardia                      2(2.2%)                         ------- 
 
.  Tachypnea                        2(2.2%)                        -------- 
 
 . Gallop rhythm                   2(2.2%)                        ------- 
 
.  Basal crepitations              2(2.2%)                        ------ 
 
.  Hemic murmur                   2(2.2%)                        ------- 
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. 3.12 Investigations: 
3. 12   Detection of parvovirus IgG and IgM antibodies: 
3.12.1 Parvovirus B19 (IgG, IgM) seropositive group:  
                 Fig (20) shows seropositive patients to parvovirus B19 
(IgG seropositive) among patients in the study population were 
52(28.9%) patients, in which 28(31.1%) hemoglobinopathic patients 
and 24(26.7%) patients of control group. 
                   Fig (21) shows seropositive (IgM) patients during aplastic 
crisis (acute infection) were eight patients (8.9%), in which six (6.7%) 
patients with hemoglobinopathies and two (2.2%) patients of control 
group.   
3.12. 2 Age distribution of seropositive group:  
                  Fig (22) shows age distribution of patients of seropositive 
among hemoglobinopathic and control patients. IgG seropositive 
group distributed as followed: 14 (50%) patients of 
hemoglobinopathies were less than five years, eight (28.6%)  were 
between 5 to less than ten,  five (17.9%) patients were between 10 
and less than 15years, and one patient (3.6%) was between 15 to 18 
years. In the control group, five (20.8%) patients were less than 5 
years, ten ((41.7%) patients were between 5 and less than 10 years, 
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six (25%) patients were between 10 to less than 15years, and three 
(12.5%) patients were between 15 to 18 years ((P= 0.7) no significant 
difference).  
                 Fig(22) shows Age distribution of patients during aplastic 
crisis (IgM seropositive) in children with hemoglobinopathies, three 
(50%) patients were less than five years, one (16.7%) patient 
between five to less than 10years, and two (33.3%) patients were 
between 10 to less than 15 years(( p=0.1) no significant difference). 
In the control group, two (100%) patients were between 15 to 18 
years ((p = 0.001) there was significant difference).   
3.12.3   Sex distribution of seropositive group: 
                 Fig (23) shows sex distribution of patients of seropositive 
group. Hemoglobinopathic children of IgG seropositive distributed as, 
14 (50%) patients were male while 14 (50%) were female ((p=0.8) no 
significant difference). In the control group, 16 (66.7%) patients were 
male, and eight (33.3%) were female ((p=0.8) no significant 
difference). 
               Fig (23) shows sex distribution of patients with aplastic crisis 
(IgM seropositive) in children with hemoglobinopathies, two (33.3%) 
patients were male, and four (66.7%) were female ((p=0.3) no 
 127
significant difference). In the control group, two (100%) patients were 
male ((p=0.2) no significant difference). 
   3.12.4 Type of hemoglobinopathy among seropositive 
group:               
                 Fig (24)  shows the type of hemoglobinopathy among 
children of IgG  seropositive, 21 (75%) patients with sickle cell 
disease, and seven (25%) patients with thalassemia((p=0.1) no 
significant difference).  
               Among patients with aplastic crisis (IgM seropositive), we 
found that four (66.7%) patients with sickle cell disease while two 
(33.3%) patients with thalassemia ((p=0.3) no significant difference).  
3.12.5 Number of hospital admission among patients of 
seropositive group: 
                 Table (5) shows  the number of hospital admission among 
IgG seropositive patients with hemoglobinopathies, four (14.3%) 
patients had no history of hospital admission, 15 (53,6%) patients 
were admitted one to five times,7(25%) were admitted six to ten times, 
and two patients admitted more than 10 times((p=0.8) no significant 
difference). In the control group, two (8.3%) patients had no history of 
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hospital admission, while 22 (91.7%) admitted one to five times 
((p=0.7) no significant difference). 
                    Table (6) shows the number of patients admitted to the 
hospital during aplastic crisis (IgM seropositive) in hemoglobinopathic 
children distributed as, one (16.7%) patient had history of hospital 
admission, Three patients (50%) had history of hospitalization from 
one to five, two (33.3%) patients had history of six to ten times((p=0.8) 
no significant difference). In the control group, there were two (100%) 
patients admitted up to five times ((p=0.2) no significant difference). 
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Fig (20) 
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Fig (21) 
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Fig (22) 
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Fig (23) 
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Fig (24) 
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Table (5): Number of hospital admissions in                           
                Patients of (IgG) seropositive group 
 
 NO. of hospital admission Patients Control 
 
NO hospital admission                4(14.3%)                       2(8.3%) 
 
  1 – 5 times                                 15(53.6%)                  22(91.7%) 
 
  5 – 10 times                                7(25%)                       ------------ 
 
? 10 times                                2(8.3%)                       ----------- 
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Table (6): Number of hospital admissions in                           
                Patients of (IgM) seropositive group 
 
 NO. of hospital admission Patients Control 
 
NO hospital admission                1(16.7%)                       -------- 
 
  1 – 5 times                                 3(50%)                       2(100%) 
 
  5 – 10 times                                2(33.3%)                       ---------- 
 
? 10 times                                2(8.3%)                       ----------- 
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 3.12.6 Risks Factors in seropositive group: 
   3.12.6.1 Number of blood transfusion among patients 
of seropositive group: 
              Table(7), (Fig25) shows  patients with IgG seropositive,13 
(46.4%) patients with hemoglobinopathies had no history of blood 
transfusion, 11 (39.2%) patients had history of one to 5 times, three 
(10.7%) patients had history of six up to ten, and one (3.6%) patient 
had history of more than ten times((p=0.08) no significant difference. 
Among control group, 24 (100%) patients had no history of blood 
transfusion.  
              Hemoglobinopathic children with aplastic crisis (IgM 
seropositive), two (33.3%) patients had no history of blood 
transfusion, four (66.7%) patients had history of one to five times 
((p=0.8) no significant difference. In the control group, two (100%) 
had no history of blood transfusion 
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3.12.6.2 Upper Respiratory Tract Infection Among 
seropositive group:               
Table (7) shows all hemoglobinopathic and control seropositive 
patients (IgG, IgM) had history of upper respiratory tract infections ((P 
=0.002) significant difference)  
 3.12.6.3 Housing condition among seropositive group:  
              Table(7) shows the housing condition among seropositive 
(IgG) patients, one (3.6%) patient had good housing condition, and 
27(97.4%) patients had bad housing condition ((p=0.001) there was 
significant difference). In control group, two (8.3%) patients had good 
housing condition, while 22 (91.7%) patients had bad housing 
condition ((p=0.002) there was significant difference).  
              Among patients with aplastic crisis (IgM seropositive), all 
patients either hemoglobinopathic ((p=0.1) no significant difference) 
or control group ((p=0.3) no significant difference) had bad housing 
condition.  
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3.12.7 History of arthralgia or arthritis, skin rash, 
palpitation in seropositive group: 
              IgG seropositive group, all 28(100%) patients with 
hemoglobinopathies had history of arthralgia or arthritis, 16 (57.1%) 
patients had skin rash ((p=0.9) no significant difference), 15(53.6%) 
patients had palpitation((p=0.07) no significant difference). In the 
control group four (16.7) patients had history of arthritis or arthralgia 
((p=0.3 no significant difference), 14(58.3%) had history of skin rash 
((P=0.03) there was significant difference), ten (41, 7%) patients had 
history of palpitation ((p=0.007) there was significant difference).  
              In children with aplastic crisis (IgM seropositive), all eight 
(100%) hemoglobinopathic patients had history of arthralgia or 
arthritis, four (66.7%) patient had skin rash((p=0.6) no significant 
difference), five (83.3%) patients had of palpitation((p=0.02) there 
was significant difference). In control group,no patient had history of 
arthralgia or arthritis((p=0.4) no significant difference), one (50%) 
patient had history of skin rash((p=0.6) no significant difference) and 
one (50%) had history of palpitation((p=0.3) no significant difference). 
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Table (7) Risk factors among seropositive (IgM) group  
(Aplastic crisis) 
Risk factor Patients Control 
 
1-Housing condition:  
.  Good                               ----------                         ---------- 
.  Bad                                6(100%)                       2(100%) 
 
2-Number of blood transfusion: 
.No history of blood         2(33.3%)                    2(100%) 
transfusion 
. 1 – 4                              4(66.7%)                       --------- 
. 5 – 10                             ----------                        --------- 
.  > 10                               ----------                         --------- 
 
3- History of upper           
Respirtory infection      6(100%)                       2(100%) 
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Fig (25) 
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3.12.8 Clinical symptoms among seropositive (IgM) 
group (Aplastic crisis): 
                Table (8) shows Hemoglobinopathic patients with aplastic 
crisis, four (66.7%) patients were presented with asymptomatic 
infection ((p=0.4) no significant difference), Four (66, 7%) with 
fatigability and malaise ((p=0.4) no significant difference). Two (33, 
3%) patients with palpitation ((p=0.2) no significant difference) and 
two (33.3%) patients with right hypochondrial pain ((p=0.007) there 
was significant difference), four (66.7%) with joint swelling and 
pain((p=0.1) no significant difference) and no patient was presented 
with skin rash. The clinical findings among seropositive patients of 
control group two (100%) patient were presented with asymptomatic 
infection and no other presenting symptom.   
3.12.9 Clinical signs among seropositive (IgM) group 
(Aplastic crisis): 
           Table (9) shows the important clinical findings among 
hemoglobinopathic patient. All patients six (100%) were pale ((P 
=0.04) there was significant difference), two (33.3%) patients had 
frontal bossing and maxillary prominence, five (83.3%) had 
hepatomeglly((p=0.8) no significant difference), two (33.3%) had 
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splenomegally((p=0.8) no significant difference), three (50%) patients 
presented with hand-foot syndrome and one (16.7%) with bone 
involvement((p=0.05) no significant difference). two (33.3%) patients 
were presented with signs heart (aplastic crisis) (P=0.00 significant 
difference)(tachypnea, tachycardia, gallop rhythm, basal crepitations, 
hemic murmur).   Among control group two (100%) patients ((P = 
0.00) there was significant difference) were pale and no patient had 
any other clinical finding.   
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Table (8): Clinical symptoms among seropositive (IgM) 
group (Aplastic crisis) 
Symptoms Patients Control 
 
Asymptomatic  4(66.7%)                        2(100%) 
Malaise                             4(66.7%)                        ----------- 
 
Palpitation                        2(33.3%)                          ----------  
    
Right hypochondrial           2(33.3%)                         ----------    
pain 
 
Skin rash                          -----------                           --------- 
 
Joint pain                          4(66.7%)                         --------- 
 
 
Joint swelling                    4(66.7%)                           -------- 
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Table(9)  clinical Signs among seropositive (IgM) group        
(Aplastic crisis): 
Signs Patients Control
 
Pallor                                    6(100%)                      2(100%)    
 
Frontal bossing                    2(33.3%)                      --------- 
 
Maxillary prominence           2(33.3%)                      -------- 
 
Hepatomegly                        5(83.3%)                       ------- 
 
Splenomegly                       2(33.3%)                         -------- 
 
Hand-foot syndrome           3(50%)                           --------- 
 
Bone involvement              1(16.7%)                          ------- 
 
 
Signs of heart failure: 
 
.  Tachycardia                     2(33.3%)                         ------- 
 
.  Tachypnea                       2(33.3%)                        -------- 
 
 . Gallop rhythm                   2(33.3%)                        ------- 
 
.  Basal crepitations              2(33.3%)                        ------ 
 
.  Hemic murmur                   2(33.3%)                        ------- 
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3.12.10 Investigations of patients with aplastic crisis: 
3.12.10.1 Hemoglobin level among patients with aplastic 
crisis:  
                   Six (100%) hemoglobinopathic patients ((p=0.00) there 
was significant difference) and two (100%) of control patients 
((p=0.00) there was significant difference) had hemoglobin level 
below the mean for age for those patients.  
3.12.10.2 Reticulocyte count among patients with 
aplastic crisis:  
                   Six (100%) hemoglobinopathic patients ((p=0.00) there 
was significant difference) and two (100%) of control patients 
((p=0.00) there was significant difference) had reticulocyte count 
below the mean for age for those patients.  
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DISCUSSION 
4.1- Socio-demographic characteristics of the study 
group:                                                                                                           
4.1.1- Age and sex characteristics: 
               The majority of hemoglobinopathic children of the study 
group were less than 15 years (90%). Only 10% of patients were 
those between 15-18 years. This may indicate that the decrease of 
the life in patients with hemoglobinopathies was due to the 
complications of hemoglobinopathies. This similar to studies done by 
Pauling and Fucharoen (86,137). 
                The ratio between male and female was found to be equal 
and this similar to the study done by Wainscoat (84). 
4.2- History: 
4.2.1-Family and social history: 
               The majority of children with hemoglobinopathies were of 
low socioeconomic class (72.2%) and this may be explained by the 
poverty, which is the predominant feature of our country which is also 
seen in the control group (64.4%). 
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                The majority of patients with hemoglobinopathies were from 
Messeria tribe (31.1%), and 69% of them had family history of 
hemoglobinopathies, and about 78% were outcome of 
consanguineous marriages. This is similar to that reported by Ahmed 
and his colleagues (85).    
             The majority of patients with hemoglobinopathies were of 
primary school education (31.1%), even though their ages were older 
for primary school, and 16.7% of patients were off school. This may 
be related to the repeated episodes of illnesses, the frequency of 
hospital admissions, and the frequency of blood transfusions. These 
results were similar to the results of the studies of Wainscoats and 
pauling (84) (86).  
4.2.2 Past medical history:  
                Regarding the past history of hospital admission in patients 
with hemoglobinopathies compared to the control group, 86.7% had 
history of 1-9 times, and 13.3% had history of hospitalization more 
than 10 times, while 86.7% of patients in the control group had history 
of hospitalization of less than three times. This can be explained by 
the complications of hemoglobinopathies as reported by Wainscoat 
study (84).   
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                      About seventy-seven eight percent of 
hemoglobinopathic patients had history of blood transfusion, while 
81.1% patients of control group had no history of blood transfusion. 
This can be explained by repeated attacks of anemia in those 
patients and this is similar to result of the study done by Hussain and 
his colleagues (88). 
4.3 Parvovirus B19 antibodies (IgG, IgM) seropositive 
group:                                                                                                          
The prevalence of parvovirus B19 infection (IgG seropositive) was 
31.1% in patients with hemoglobinopathies and 26.7% patients of 
control group  no statistical significant difference (P=0.5) and this is 
similar to the study done by Truscher (164).  
                       In addition, there was no statistical significant 
difference between the age of children and the prevalence of 
parvovirus B19 (IgG seropositive) in patients with 
hemoglobinopathies (p=0.1) and patients of control group (p=0.7) and 
this is similar to Truscher’s result (164).  
                      Furthermore, there was no statistical significant 
difference between the prevalence of parvovirus B19 infection and 
the sex of the patients in both groups( hemoglobinopathies (P=0.8) 
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as well as that of control group (P=0.6)). This result is similar to the 
study done by Truscher  (164). 
                     In addition, there was no statistical significant difference 
between the prevalence of parvovirus B19 (IgG seropositive) and the 
type of hemoglobinopathy (p=0.1) and this is similar to the study done 
by Badr (172).  
                Also, there was no statistical significant difference between 
the prevalence of parvovirus B19 infection (IgG seropositie) and the 
residence of children in both groups ( hemoglobinopathies (p=0.1) 
and control group (0.07) )and this may be due to the same 
transmission rate in urban, rural and suburban areas. This result is 
against the  study done by Truscher’(164).  
4.4 Risk Factors of seropositive group: 
              There was statistical significant difference between the 
prevalence parvovirus B19 infection ( IgG seropositive) and housing 
condition in patients with hemoglobinopathies (p=0.001) and of 
control group (p=0.002). This result showed that the transmission of 
B19 was by respiratory route and this is similar to the study done by 
Shiraishi and his colleagues (21).  
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             Since all patients (hemoglobinopathic and control) had 
history of upper respiratory infection, so there was no  statistical 
significant difference. 
                No  statistical significant difference between the prevalence 
parvovirus B19 (IgG seropositive) and number of blood transfusion of 
patients with hemoglobinopathies (p=0.8) and this was against to the 
study done by Zanella and his colleagues (167). 
4.5 History of arthralgia or arthritis, skin rash among 
seropositive (IgG) group: 
              There was no statistical significant difference between the 
prevalence of parvovirus B19 infection (IgG seropositive) and history 
of arthritis or arthralgia in patients with hemoglobinopathies (P=0.3), 
and this can explained by the incidence of arthralgia in children with 
B19 is uncommon and this result is similar to the study done by Reid 
(34).   
               In addition, there was no  statistical significant difference 
between the prevalence of parvovirus B19 (IgG seropositive) and 
history of skin rash (Erythema Infectiosum), and this can be explained 
by the occurrence of this rash was rare in children especially those 
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with aplastic crisis and this result is similar to the result of Balfour’ 
study (33).   
4.6 Clinical symptoms and signs among patients with 
aplastic crisis (IgM seropositive):  
              In spite of there was no statistical significant difference 
between a symptomatic infection  and the occurrence of aplastic 
crisis (p=0.4), 33.3% of patients with aplastic crisis have a 
symptomatic infection, and this result similar to Woolf and his 
colleagues result that 25% of aplastic crisis could be a symptomatic 
(31).  
             In addition, there was no statistical significant difference 
between symptoms of acute infection like fatigability and malaise (P= 
0.4) palpitation (P=0.2), joint pain and smelling (P=0.1), skin rash 
(P=0.8) and the occurrence of aplastic crisis (IgM seropositive) and 
this was consistent with the result done by Quian (79). However there 
was statistical significant difference between right hypochondrial and 
abdominal pain (p=0.007) and aplastic crisis and this may be 
explained by right hypochondrial or abdominal pain could be sign of 
acute anemia and this was similar to the study done by Muir’s (80). 
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               Pallor had statistical significant difference (P=0.04) with the 
occurrence of aplastic crisis (IgM seropositive) and this result was 
similar to the result of Muir (80). 
                Furthermore, there was statistical significant difference 
between the presence of murmur (p=0.005), gallop rhythm (p=0.00), 
and basal crackles (p=0.00) and the occurrence of aplastic crisis. 
This result consistent with Muir result (80) since marked drop in 
hemoglobin level may lead to acute anemia, or may progressed to 
anemic heart failure especially in hemoglobinopathic patients (80).  
              There was no statistical significant difference between the 
occurrence of aplastic crisis (IgM seropositive) and the presence of 
arthritis , since arthritis rarely associated with aplastic crisis and this 
is similar to the study done by Balfour’s (79).  
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CONCLUSION 
                 The prevalence of parvovirus B19 (IgG seropositive) in 
children with hemoglobinopathies was 31.1%, while in normal 
children was found to be 26.7%. 
                The incidence of acute infection (IgM seropositive) was 
6.7% in patients with hemoglobinopathies and 2.2% in normal 
children.  
              Regarding the age, sex, types of hemoglobinopathies, 
residence of the study group, and number of hospital admission, 
there was no statistical significant difference between them as well as 
the prevalence of parvovirus B19 in both the hemoglobinopathic and 
control group. 
           There was statistical significant difference between the 
prevalence of parvovirus B19 (IgG seropositive) and housing 
condition, this proved that the transmission of parvovirus B19 is 
mainly through respiratory route in both study groups. 
             There was no statistically significant difference between the 
incidence of acute infection (IgM seropositive) and the occurrence of 
clinical symptoms of fatigability and malaise, joint pain and swelling, 
and skin rash. However, there was statistical significant difference 
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between the presence of palpitation, right hypochondrial pain or 
abdominal pain and the occurrence of aplastic crisis (IgM 
seropositive). 
              In addition, there was statistical significant difference 
between the incidence of acute infection (IgM seropositive) and the 
presence of clinical signs of aplastic crisis, which include the 
presence of pallor, murmur, gallop rhythm, and basal crackles and 
proved laboratory by low hemoglobin and reticulocytopenia.      
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RECOMMEDATIONS 
 
 
1. It is highly important to establish the screening program for 
parvovirus B19 and this should be implemented in all blood 
banks. 
2.  It will be significantly beneficial to conduct diagnostic and 
treatment program of parvovirus B19 especially for patients with 
hemoglobinopathies. 
3. It is recommended to develop better guidelines and techniques 
for the diagnosis and treatment protocols of the thalassemic 
patients in Sudan. 
4. Further studies are recommended in other aspects or health 
problems associated with parvovirus B19 infections in patients with 
hemoglobinopathies. 
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Table (1) 
Education level of the parents of the study population             
(n= 180 ) 
 
Education 
 
 
Illiterate 
Primary 
Intermediate 
secondary 
university 
     Father                                        Mother
Patients 
 
34 (37.8 %) 
24(26.7%) 
14(15.6%) 
16(17.8%) 
2(2.2%) 
Control 
 
8(8.9%) 
22(24.4%)
22(24.4%)
29(32.2%)
9(10%) 
Patients 
 
54(60%) 
13(14.4%) 
16(17.8%) 
5(5.6%) 
2(2.2%) 
Control 
 
9(10%) 
26(28.9) 
42(46.7%)
13(14.4%)
ــــــــــــــــــــ 
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Table (2) 
Parent’s occupation of children of the study population          
(n= 180) 
 
Occupation Father Mother 
 
Professional 
Employee 
Laborer 
Skilled 
laborer  
Running 
small 
business 
House-wife 
Patients control Patients Control 
9(10%) 
28(31.1%) 
32(35.6%) 
20(22.2%) 
 
1(1.1%) 
 
   
   0 
2(2.2%) 
10(11.1%) 
65(72.2%) 
6(6.7%) 
 
7(7.8%) 
 
 
     0 
2(2.2%) 
0% 
1(1.1%) 
    0% 
 
22(24.4) 
 
 
65(72.2%) 
0% 
1(1.1%) 
1(1.1%) 
    0% 
 
14(15.6%)
 
 
74(82.2%)
 
 
Table (3) 
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Number of hospital admissions among children in the study 
population (n = 180) 
 
No. hospital admission  Patients Control group 
1 – 5 times 
6 – 10 times 
More than 10 times 
(67.8%) 
17=18.9% 
12(13.3%) 
88(97.8%) 
2(2.2%) 
0 
 
 
 
 
 
 
 
 
 
 
Table (4)  
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Number of blood transfusion among children in the study 
group. (n = 180) 
 
No. of blood 
transfusion 
Patients with 
hemoglobinopathies 
Control 
No. blood 
transfusion 
20 (22.2 % ) 73 (81.1 % ) 
1 – 5 times 30 (33.3 % ) 17 (18.9 % ) 
7 – 10  27(30 %) ------------ 
More than 10 
times 
13(14.4 %) ------------ 
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Table (5): 
The presenting symptoms among children in the study 
population (n = 180)  
 
Symptoms    
No complain 48(53.3%) 2(2.2%) 
Fatigability 57(63.3%) 46(51.1%) 
Malaise 57(63.3%) 46(51.1%) 
Palpitation 35(38.9%) 13(14.4%) 
Right 
hypochondrial pain 
10(11.1%) 2(2.2%) 
Arthralgia 42(46.7%) 22(24.4) 
Skin rash 0 2(2.2%) 
Others -------------- ------------- 
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Table (6): 
The presenting clinical signs of children of the study 
population      (n = 180) 
 
Clinical signs patients Control 
General condition   
Well 31(34.4%) 58(64.4) 
Ill 57(63.3%) 32(35.6%) 
Pallor 65(72.2%) 11(12.2%) 
Frontal – bossing  13(14.4%) 0 
Maxillary 
prominence 
13(14.4%) 0 
Cardiopulmonary 
examination 
  
Apex   
Normal 75(83.3%) 86(95.6%) 
Displaced 15(16.7%) 4(4.4) 
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Murmur 18(20%) 6(6.7%) 
Basal crackles 2(2.2%) ------------ 
Gallop rhythm. 2(2.2%) ------------- 
Abdominal 
examination 
  
Hepatomegally 80(88.9%) 15(16.7%) 
Splenomegally 28(31.1%) 10(11.1%) 
Musculoskeletal 
examination 
  
Arthritis 28(30%) 6(6.7%) 
Other ------------ ----------- 
 
 
 
 
 
 
